IAN THOMPSON

TitleAdjunct Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Urology
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Julián-Serrano S, Yuan F, Wheeler W, Benyamin B, Machiela MJ, Arslan AA, Beane-Freeman LE, Bracci PM, Duell EJ, Du M, Gallinger S, Giles GG, Goodman PJ, Kooperberg C, Marchand LL, Neale RE, Shu XO, Van Den Eeden SK, Visvanathan K, Zheng W, Albanes D, Andreotti G, Ardanaz E, Babic A, Berndt SI, Brais LK, Brennan P, Bueno-de-Mesquita B, Buring JE, Chanock SJ, Childs EJ, Chung CC, Fabiánová E, Foretová L, Fuchs CS, Gaziano JM, Gentiluomo M, Giovannucci EL, Goggins MG, Hackert T, Hartge P, Hassan MM, Holcátová I, Holly EA, Hung RI, Janout V, Kurtz RC, Lee IM, Malats N, McKean D, Milne RL, Newton CC, Oberg AL, Perdomo S, Peters U, Porta M, Rothman N, Schulze MB, Sesso HD, Silverman DT, Thompson IM, Wactawski-Wende J, Weiderpass E, Wenstzensen N, White E, Wilkens LR, Yu H, Zeleniuch-Jacquotte A, Zhong J, Kraft P, Li D, Campbell PT, Petersen GM, Wolpin BM, Risch HA, Amundadottir LT, Klein AP, Yu K, Stolzenberg-Solomon RZ. Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. Am J Clin Nutr. 2021 10 04; 114(4):1408-1417. PMID: 34258619.
      Citations:    Fields:    
    2. Kirk PS, Zhu K, Zheng Y, Newcomb LF, Schenk JM, Brooks JD, Carroll PR, Dash A, Ellis WJ, Filson CP, Gleave ME, Liss M, Martin F, McKenney JK, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Gore JL. Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. Cancer. 2021 Sep 13. PMID: 34516660.
      Citations:    Fields:    
    3. Karunamuni RA, Huynh-Le MP, Fan CC, Thompson W, Lui A, Martinez ME, Rose BS, Mahal B, Eeles RA, Kote-Jarai Z, Muir K, Lophatananon A, Tangen CM, Goodman PJ, Thompson IM, Blot WJ, Zheng W, Kibel AS, Drake BF, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Park JY, Lin HY, Taylor JA, Bensen JT, Mohler JL, Fontham ETH, Multigner L, Blanchet P, Brureau L, Romana M, Leach RJ, John EM, Fowke JH, Bush WS, Aldrich MC, Crawford DC, Cullen J, Petrovics G, Parent MÉ, Hu JJ, Sanderson M, Mills IG, Andreassen OA, Dale AM, Seibert TM. Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24. Prostate Cancer Prostatic Dis. 2021 Jun 14. PMID: 34127801.
      Citations:    Fields:    
    4. Osmulski PA, Cunsolo A, Chen M, Qian Y, Lin CL, Hung CN, Mahalingam D, Kirma NB, Chen CL, Taverna JA, Liss MA, Thompson IM, Huang TH, Gaczynska ME. Contacts with Macrophages Promote an Aggressive Nanomechanical Phenotype of Circulating Tumor Cells in Prostate Cancer. Cancer Res. 2021 Aug 01; 81(15):4110-4123. PMID: 34045187.
      Citations:    Fields:    
    5. Conti DV, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A, Schumacher FR, Olama AAA, Benlloch S, Dadaev T, Brook MN, Sahimi A, Hoffmann TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Muir K, Lophatananon A, Wan P, Le Marchand L, Wilkens LR, Stevens VL, Gapstur SM, Carter BD, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Giles GG, Southey MC, MacInnis RJ, Cybulski C, Wokolorczyk D, Lubinski J, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nordestgaard BG, Nielsen SF, Weischer M, Bojesen SE, Røder MA, Iversen P, Batra J, Chambers S, Moya L, Horvath L, Clements JA, Tilley W, Risbridger GP, Gronberg H, Aly M, Szulkin R, Eklund M, Nordström T, Pashayan N, Dunning AM, Ghoussaini M, Travis RC, Key TJ, Riboli E, Park JY, Sellers TA, Lin HY, Albanes D, Weinstein SJ, Mucci LA, Giovannucci E, Lindstrom S, Kraft P, Hunter DJ, Penney KL, Turman C, Tangen CM, Goodman PJ, Thompson IM, Hamilton RJ, Fleshner NE, Finelli A, Parent MÉ, Stanford JL, Ostrander EA, Geybels MS, Koutros S, Freeman LEB, Stampfer M, Wolk A, Håkansson N, Andriole GL, Hoover RN, Machiela MJ, Sørensen KD, Borre M, Blot WJ, Zheng W, Yeboah ED, Mensah JE, Lu YJ, Zhang HW, Feng N, Mao X, Wu Y, Zhao SC, Sun Z, Thibodeau SN, McDonnell SK, Schaid DJ, West CML, Burnet N, Barnett G, Maier C, Schnoeller T, Luedeke M, Kibel AS, Drake BF, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Koudou YA, John EM, Grindedal EM, Maehle L, Khaw KT, Ingles SA, Stern MC, Vega A, Gómez-Caamaño A, Fachal L, Rosenstein BS, Kerns SL, Ostrer H, Teixeira MR, Paulo P, Brandão A, Watya S, Lubwama A, Bensen JT, Fontham ETH, Mohler J, Taylor JA, Kogevinas M, Llorca J, Castaño-Vinyals G, Cannon-Albright L, Teerlink CC, Huff CD, Strom SS, Multigner L, Blanchet P, Brureau L, Kaneva R, Slavov C, Mitev V, Leach RJ, Weaver B, Brenner H, Cuk K, Holleczek B, Saum KU, Klein EA, Hsing AW, Kittles RA, Murphy AB, Logothetis CJ, Kim J, Neuhausen SL, Steele L, Ding YC, Isaacs WB, Nemesure B, Hennis AJM, Carpten J, Pandha H, Michael A, De Ruyck K, De Meerleer G, Ost P, Xu J, Razack A, Lim J, Teo SH, Newcomb LF, Lin DW, Fowke JH, Neslund-Dudas C, Rybicki BA, Gamulin M, Lessel D, Kulis T, Usmani N, Singhal S, Parliament M, Claessens F, Joniau S, Van den Broeck T, Gago-Dominguez M, Castelao JE, Martinez ME, Larkin S, Townsend PA, Aukim-Hastie C, Bush WS, Aldrich MC, Crawford DC, Srivastava S, Cullen JC, Petrovics G, Casey G, Roobol MJ, Jenster G, van Schaik RHN, Hu JJ, Sanderson M, Varma R, McKean-Cowdin R, Torres M, Mancuso N, Berndt SI, Van Den Eeden SK, Easton DF, Chanock SJ, Cook MB, Wiklund F, Nakagawa H, Witte JS, Eeles RA, Kote-Jarai Z, Haiman CA. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021 Mar; 53(3):413. PMID: 33473200.
      Citations: 1     Fields:    
    6. Pal SK, Tangen C, Thompson IM, Balzer-Haas N, George DJ, Heng DYC, Shuch B, Stein M, Tretiakova M, Humphrey P, Adeniran A, Narayan V, Bjarnason GA, Vaishampayan U, Alva A, Zhang T, Cole S, Plets M, Wright J, Lara PN. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet. 2021 02 20; 397(10275):695-703. PMID: 33592176.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    7. Mocci E, Kundu P, Wheeler W, Arslan AA, Beane-Freeman LE, Bracci PM, Brennan P, Canzian F, Du M, Gallinger S, Giles GG, Goodman PJ, Kooperberg C, Le Marchand L, Neale RE, Shu XO, Visvanathan K, White E, Zheng W, Albanes D, Andreotti G, Babic A, Bamlet WR, Berndt SI, Blackford AL, Bueno-de-Mesquita B, Buring JE, Campa D, Chanock SJ, Childs EJ, Duell EJ, Fuchs CS, Gaziano JM, Giovannucci EL, Goggins MG, Hartge P, Hassan MM, Holly EA, Hoover RN, Hung RJ, Kurtz RC, Lee IM, Malats N, Milne RL, Ng K, Oberg AL, Panico S, Peters U, Porta M, Rabe KG, Riboli E, Rothman N, Scelo G, Sesso HD, Silverman DT, Stevens VL, Strobel O, Thompson IM, Tjonneland A, Trichopoulou A, Van Den Eeden SK, Wactawski-Wende J, Wentzensen N, Wilkens LR, Yu H, Yuan F, Zeleniuch-Jacquotte A, Amundadottir LT, Li D, Jacobs EJ, Petersen GM, Wolpin BM, Risch HA, Kraft P, Chatterjee N, Klein AP, Stolzenberg-Solomon R. Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. Cancer Res. 2021 06 01; 81(11):3134-3143. PMID: 33574088.
      Citations: 1     Fields:    
    8. Flaig TW, Tangen CM, Daneshmand S, Alva A, Lerner SP, Lucia MS, McConkey DJ, Theodorescu D, Goldkorn A, Milowsky MI, Bangs R, MacVicar GR, Bastos BR, Fowles JS, Gustafson DL, Plets M, Thompson IM. A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clin Cancer Res. 2021 May 01; 27(9):2435-2441. PMID: 33568346.
      Citations: 4     Fields:    
    9. Chadid S, Song X, Schenk JM, Gurel B, Lucia MS, Thompson IM, Neuhouser ML, Goodman PJ, Parnes HL, Lippman SM, Nelson WG, De Marzo AM, Platz EA. Association of Serum Carotenoids and Retinoids with Intraprostatic Inflammation in Men without Prostate Cancer or Clinical Indication for Biopsy in the Placebo Arm of the Prostate Cancer Prevention Trial. Nutr Cancer. 2021 Jan 29; 1-8. PMID: 33511883.
      Citations:    Fields:    
    10. Kemp Bohan PM, Chick RC, O'Shea AE, Vreeland TJ, Hickerson AT, Cindass JL, Ensley DC, Hale D, Clifton GT, Sohn VY, Thompson IM, Peoples GE, Liss MA. Phase I Trial of Encapsulated Rapamycin in Patients with Prostate Cancer Under Active Surveillance to Prevent Progression. Cancer Prev Res (Phila). 2021 May; 14(5):551-562. PMID: 33514567.
      Citations: 1     Fields:    
    11. Goldkorn A, Tangen C, Plets M, Morrison GJ, Cunha A, Xu T, Pinski JK, Ingles SA, Triche T, Harzstark AL, Kohli M, MacVicar GR, Vaena DA, Crispino AW, McConkey DJ, Lara PN, Hussain MHA, Quinn DI, Vogelzang NJ, Thompson IM, Agarwal N. Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216). Clin Cancer Res. 2021 Apr 01; 27(7):1967-1973. PMID: 33500355.
      Citations:    Fields:    
    12. Conti DV, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A, Schumacher FR, Olama AAA, Benlloch S, Dadaev T, Brook MN, Sahimi A, Hoffmann TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Muir K, Lophatananon A, Wan P, Le Marchand L, Wilkens LR, Stevens VL, Gapstur SM, Carter BD, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Giles GG, Southey MC, MacInnis RJ, Cybulski C, Wokolorczyk D, Lubinski J, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nordestgaard BG, Nielsen SF, Weischer M, Bojesen SE, Røder MA, Iversen P, Batra J, Chambers S, Moya L, Horvath L, Clements JA, Tilley W, Risbridger GP, Gronberg H, Aly M, Szulkin R, Eklund M, Nordström T, Pashayan N, Dunning AM, Ghoussaini M, Travis RC, Key TJ, Riboli E, Park JY, Sellers TA, Lin HY, Albanes D, Weinstein SJ, Mucci LA, Giovannucci E, Lindstrom S, Kraft P, Hunter DJ, Penney KL, Turman C, Tangen CM, Goodman PJ, Thompson IM, Hamilton RJ, Fleshner NE, Finelli A, Parent MÉ, Stanford JL, Ostrander EA, Geybels MS, Koutros S, Freeman LEB, Stampfer M, Wolk A, Håkansson N, Andriole GL, Hoover RN, Machiela MJ, Sørensen KD, Borre M, Blot WJ, Zheng W, Yeboah ED, Mensah JE, Lu YJ, Zhang HW, Feng N, Mao X, Wu Y, Zhao SC, Sun Z, Thibodeau SN, McDonnell SK, Schaid DJ, West CML, Burnet N, Barnett G, Maier C, Schnoeller T, Luedeke M, Kibel AS, Drake BF, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Koudou YA, John EM, Grindedal EM, Maehle L, Khaw KT, Ingles SA, Stern MC, Vega A, Gómez-Caamaño A, Fachal L, Rosenstein BS, Kerns SL, Ostrer H, Teixeira MR, Paulo P, Brandão A, Watya S, Lubwama A, Bensen JT, Fontham ETH, Mohler J, Taylor JA, Kogevinas M, Llorca J, Castaño-Vinyals G, Cannon-Albright L, Teerlink CC, Huff CD, Strom SS, Multigner L, Blanchet P, Brureau L, Kaneva R, Slavov C, Mitev V, Leach RJ, Weaver B, Brenner H, Cuk K, Holleczek B, Saum KU, Klein EA, Hsing AW, Kittles RA, Murphy AB, Logothetis CJ, Kim J, Neuhausen SL, Steele L, Ding YC, Isaacs WB, Nemesure B, Hennis AJM, Carpten J, Pandha H, Michael A, De Ruyck K, De Meerleer G, Ost P, Xu J, Razack A, Lim J, Teo SH, Newcomb LF, Lin DW, Fowke JH, Neslund-Dudas C, Rybicki BA, Gamulin M, Lessel D, Kulis T, Usmani N, Singhal S, Parliament M, Claessens F, Joniau S, Van den Broeck T, Gago-Dominguez M, Castelao JE, Martinez ME, Larkin S, Townsend PA, Aukim-Hastie C, Bush WS, Aldrich MC, Crawford DC, Srivastava S, Cullen JC, Petrovics G, Casey G, Roobol MJ, Jenster G, van Schaik RHN, Hu JJ, Sanderson M, Varma R, McKean-Cowdin R, Torres M, Mancuso N, Berndt SI, Van Den Eeden SK, Easton DF, Chanock SJ, Cook MB, Wiklund F, Nakagawa H, Witte JS, Eeles RA, Kote-Jarai Z, Haiman CA. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021 01; 53(1):65-75. PMID: 33398198.
      Citations: 14     Fields:    Translation:Humans
    13. Cooperberg MR, Zheng Y, Faino AV, Newcomb LF, Zhu K, Cowan JE, Brooks JD, Dash A, Gleave ME, Martin F, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Carroll PR, Lin DW. Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. JAMA Oncol. 2020 10 01; 6(10):e203187. PMID: 32852532.
      Citations: 2     Fields:    Translation:Humans
    14. Karunamuni RA, Huynh-Le MP, Fan CC, Thompson W, Eeles RA, Kote-Jarai Z, Muir K, Lophatananon A, Tangen CM, Goodman PJ, Thompson IM, Blot WJ, Zheng W, Kibel AS, Drake BF, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Park JY, Lin HY, Bensen JT, Fontham ETH, Mohler JL, Taylor JA, Multigner L, Blanchet P, Brureau L, Romana M, Leach RJ, John EM, Fowke J, Bush WS, Aldrich M, Crawford DC, Srivastava S, Cullen JC, Petrovics G, Parent MÉ, Hu JJ, Sanderson M, Mills IG, Andreassen OA, Dale AM, Seibert TM. African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer. Int J Cancer. 2021 01 01; 148(1):99-105. PMID: 32930425.
      Citations: 3     Fields:    Translation:Humans
    15. Ghoneim DH, Zhu J, Zheng W, Long J, Murff HJ, Ye F, Setiawan VW, Wilkens LR, Khankari NK, Haycock P, Antwi SO, Yang Y, Arslan AA, Beane Freeman LE, Bracci PM, Canzian F, Du M, Gallinger S, Giles GG, Goodman PJ, Kooperberg C, Le Marchand L, Neale RE, Scelo G, Visvanathan K, White E, Albanes D, Amiano P, Andreotti G, Babic A, Bamlet WR, Berndt SI, Brais LK, Brennan P, Bueno-de-Mesquita B, Buring JE, Campbell PT, Rabe KG, Chanock SJ, Duggal P, Fuchs CS, Gaziano JM, Goggins MG, Hackert T, Hassan MM, Helzlsouer KJ, Holly EA, Hoover RN, Katske V, Kurtz RC, Lee IM, Malats N, Milne RL, Murphy N, Oberg AL, Porta M, Rothman N, Sesso HD, Silverman DT, Thompson IM, Wactawski-Wende J, Wang X, Wentzensen N, Yu H, Zeleniuch-Jacquotte A, Yu K, Wolpin BM, Jacobs EJ, Duell EJ, Risch HA, Petersen GM, Amundadottir LT, Kraft P, Klein AP, Stolzenberg-Solomon RZ, Shu XO, Wu L. Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2020 12; 29(12):2735-2739. PMID: 32967863.
      Citations:    Fields:    
    16. Ramsey SD, Hall IJ, Smith JL, Ekwueme DU, Fedorenko CR, Kreizenbeck K, Bansal A, Thompson IM, Penson DF. A comparison of general, genitourinary, bowel, and sexual quality of life among long term survivors of prostate, bladder, colorectal, and lung cancer. J Geriatr Oncol. 2021 03; 12(2):305-311. PMID: 32739353.
      Citations:    Fields:    Translation:Humans
    17. Christen WG, Darke AK, Gaziano JM, Glynn RJ, Goodman PJ, Minasian LM, Thompson IM. Age-related macular degeneration in a randomized trial of selenium and vitamin E in men: the Select Eye Endpoints (SEE) study (SWOG S0000B). Acta Ophthalmol. 2021 Mar; 99(2):e285-e287. PMID: 32701201.
      Citations:    Fields:    Translation:Humans
    18. Yuan F, Hung RJ, Walsh N, Zhang H, Platz EA, Wheeler W, Song L, Arslan AA, Beane Freeman LE, Bracci P, Canzian F, Du M, Gallinger S, Giles GG, Goodman PJ, Kooperberg C, Le Marchand L, Neale RE, Rosendahl J, Scelo G, Shu XO, Visvanathan K, White E, Zheng W, Albanes D, Amiano P, Andreotti G, Babic A, Bamlet WR, Berndt SI, Brennan P, Bueno-de-Mesquita B, Buring JE, Campbell PT, Chanock SJ, Fuchs CS, Gaziano JM, Goggins MG, Hackert T, Hartge P, Hassan MM, Holly EA, Hoover RN, Katzke V, Kirsten H, Kurtz RC, Lee IM, Malats N, Milne RL, Murphy N, Ng K, Oberg AL, Porta M, Rabe KG, Real FX, Rothman N, Sesso HD, Silverman DT, Thompson IM, Wactawski-Wende J, Wang X, Wentzensen N, Wilkens LR, Yu H, Zeleniuch-Jacquotte A, Shi J, Duell EJ, Amundadottir LT, Li D, Petersen GM, Wolpin BM, Risch HA, Yu K, Klein AP, Stolzenberg-Solomon R. Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. Cancer Res. 2020 09 15; 80(18):4004-4013. PMID: 32641412.
      Citations:    Fields:    Translation:Humans
    19. Hurwitz LM, Kulac I, Gumuskaya B, Valle JABD, Benedetti I, Pan F, Liu JO, Marrone MT, Arnold KB, Goodman PJ, Tangen CM, Lucia MS, Thompson IM, Drake CG, Isaacs WB, Nelson WG, De Marzo AM, Platz EA. Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila). 2020 10; 13(10):853-862. PMID: 32581009.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    20. Tang H, Jiang L, Stolzenberg-Solomon RZ, Arslan AA, Beane Freeman LE, Bracci PM, Brennan P, Canzian F, Du M, Gallinger S, Giles GG, Goodman PJ, Kooperberg C, Le Marchand L, Neale RE, Shu XO, Visvanathan K, White E, Zheng W, Albanes D, Andreotti G, Babic A, Bamlet WR, Berndt SI, Blackford A, Bueno-de-Mesquita B, Buring JE, Campa D, Chanock SJ, Childs E, Duell EJ, Fuchs C, Gaziano JM, Goggins M, Hartge P, Hassam MH, Holly EA, Hoover RN, Hung RJ, Kurtz RC, Lee IM, Malats N, Milne RL, Ng K, Oberg AL, Orlow I, Peters U, Porta M, Rabe KG, Rothman N, Scelo G, Sesso HD, Silverman DT, Thompson IM, Tjønneland A, Trichopoulou A, Wactawski-Wende J, Wentzensen N, Wilkens LR, Yu H, Zeleniuch-Jacquotte A, Amundadottir LT, Jacobs EJ, Petersen GM, Wolpin BM, Risch HA, Chatterjee N, Klein AP, Li D, Kraft P, Wei P. Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Cancer Epidemiol Biomarkers Prev. 2020 09; 29(9):1784-1791. PMID: 32546605.
      Citations: 2     Fields:    
    21. Chadid S, Barber JR, Nelson WG, Gurel B, Lucia MS, Thompson IM, Goodman PJ, Stanczyk FZ, Parnes HL, Lippman SM, De Marzo AM, Platz EA. The association between serum sex steroid hormone concentrations and intraprostatic inflammation in men without prostate cancer and irrespective of clinical indication for biopsy in the placebo arm of the Prostate Cancer Prevention Trial. Prostate. 2020 08; 80(11):895-905. PMID: 32506665.
      Citations:    Fields:    Translation:Humans
    22. Darst BF, Wan P, Sheng X, Bensen JT, Ingles SA, Rybicki BA, Nemesure B, John EM, Fowke JH, Stevens VL, Berndt SI, Huff CD, Strom SS, Park JY, Zheng W, Ostrander EA, Walsh PC, Srivastava S, Carpten J, Sellers TA, Yamoah K, Murphy AB, Sanderson M, Crawford DC, Gapstur SM, Bush WS, Aldrich MC, Cussenot O, Yeager M, Petrovics G, Cullen J, Neslund-Dudas C, Kittles RA, Xu J, Stern MC, Kote-Jarai Z, Govindasami K, Chokkalingam AP, Multigner L, Parent ME, Menegaux F, Cancel-Tassin G, Kibel AS, Klein EA, Goodman PJ, Drake BF, Hu JJ, Clark PE, Blanchet P, Casey G, Hennis AJM, Lubwama A, Thompson IM, Leach R, Gundell SM, Pooler L, Xia L, Mohler JL, Fontham ETH, Smith GJ, Taylor JA, Eeles RA, Brureau L, Chanock SJ, Watya S, Stanford JL, Mandal D, Isaacs WB, Cooney K, Blot WJ, Conti DV, Haiman CA. A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. Eur Urol. 2020 09; 78(3):316-320. PMID: 32409115.
      Citations: 3     Fields:    Translation:HumansCells
    23. Liss MA, Newcomb LF, Zheng Y, Garcia MP, Filson CP, Boyer H, Brooks JD, Carroll PR, Cooperberg MR, Ellis WJ, Gleave ME, Martin FM, Morgan T, Nelson PS, Wagner AA, Thompson IM, Lin DW. Magnetic Resonance Imaging for the Detection of High Grade Cancer in the Canary Prostate Active Surveillance Study. J Urol. 2020 10; 204(4):701-706. PMID: 32343189.
      Citations: 4     Fields:    Translation:Humans
    24. Lin DW, Zheng Y, McKenney JK, Brown MD, Lu R, Crager M, Boyer H, Tretiakova M, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Kolb S, Liss M, Morgan TM, Thompson IM, Wagner AA, Tsiatis A, Pingitore A, Nelson PS, Newcomb LF. 17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. J Clin Oncol. 2020 05 10; 38(14):1549-1557. PMID: 32130059.
      Citations: 13     Fields:    Translation:Humans
    25. Torkko K, Till C, Tangen CM, Goodman PJ, Song X, Schenk JM, Lucia MS, Peters U, van Bokhoven A, Thompson IM, Neuhouser ML. Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila). 2020 06; 13(6):521-530. PMID: 32102946.
      Citations: 1     Fields:    Translation:Humans
    26. Wong RL, Duong MT, Tangen CM, Agarwal N, Cheng HH, Vogelzang NJ, Hussain M, Thompson IM, Quinn DI, Yu EY. Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2020 09; 23(3):486-493. PMID: 32055002.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    27. Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM, Chi KN, De Bono JS, Araujo JC, Logothetis C, Eisenberger MA, Quinn DI, Fizazi K, Morris MJ, Higano CS, Tannock IF, Small EJ, Kelly WK. Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. JNCI Cancer Spectr. 2020 Apr; 4(2):pkaa003. PMID: 32368717.
      Citations:    
    28. Schenk JM, Newcomb LF, Zheng Y, Faino AV, Zhu K, Nyame YA, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW. Reply by Authors. J Urol. 2020 04; 203(4):733. PMID: 31951502.
      Citations:    Fields:    
    29. Caplash S, Kodati S, Cheng SK, Akanda M, Vitale S, Thompson I, Gangaputra S, Sen HN. Repeatability of Optical Coherence Tomography Angiography in Uveitic Eyes. Transl Vis Sci Technol. 2019 Nov; 8(6):17. PMID: 31772828.
      Citations: 2     
    30. Cheng SK, Thompson I, Okeagu C, Nida H. CHOROIDAL LESIONS UNRESPONSIVE TO FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT IN BIRDSHOT CHORIORETINOPATHY. Retin Cases Brief Rep. 2019 Oct 31. PMID: 31688672.
      Citations:    Fields:    
    31. Schenk JM, Newcomb LF, Zheng Y, Faino AV, Zhu K, Nyame YA, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW. African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study. J Urol. 2020 04; 203(4):727-733. PMID: 31651227.
      Citations: 6     Fields:    Translation:Humans
    32. Tangen CM, Schenk J, Till C, Goodman PJ, Barrington W, Lucia MS, Thompson IM. Variations in prostate biopsy recommendation and acceptance confound evaluation of risk factors for prostate cancer: Examining race and BMI. Cancer Epidemiol. 2019 12; 63:101619. PMID: 31639607.
      Citations: 1     Fields:    Translation:Humans
    33. Thompson IM, Tangen CM, Kramer B. 5a-Reductase Inhibitor Use in Patients With Prostate Cancer. JAMA Intern Med. 2019 10 01; 179(10):1440. PMID: 31589258.
      Citations:    Fields:    Translation:Humans
    34. Venkatramani V, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DA, Quek ML, Dash A, Kibel AS, Pruthi RS, Montgomery JS, Weight CJ, Sharp DS, Chang SS, Cookson MS, Gupta GN, Gorbonos A, Uchio EM, Skinner E, Soodana-Prakash N, Becerra MF, Swain S, Kendrick K, Smith JA, Thompson IM, Parekh DJ. Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup. J Urol. 2020 03; 203(3):522-529. PMID: 31549935.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    35. Pisansky TM, Thompson IM, Valicenti RK, D'Amico AV, Selvarajah S. Adjuvant and Salvage Radiotherapy after Prostatectomy: ASTRO/AUA Guideline Amendment 2018-2019. J Urol. 2019 09; 202(3):533-538. PMID: 31042111.
      Citations: 14     Fields:    Translation:Humans
    36. Synold TW, Plets M, Tangen CM, Heath EI, Palapattu GS, Mack PC, Stein MN, Meng MV, Lara P, Vogelzang NJ, Thompson IM, Ryan CW. Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249). Kidney Cancer. 2019 Aug 07; 3(2):111-118. PMID: 31763512.
      Citations: 2     
    37. Du Z, Hopp H, Ingles SA, Huff C, Sheng X, Weaver B, Stern M, Hoffmann TJ, John EM, Van Den Eeden SK, Strom S, Leach RJ, Thompson IM, Witte JS, Conti DV, Haiman CA. A genome-wide association study of prostate cancer in Latinos. Int J Cancer. 2020 04 01; 146(7):1819-1826. PMID: 31226226.
      Citations: 8     Fields:    Translation:Humans
    38. Sharp AM, Lertphinyowong S, Yee SS, Paredes D, Gelfond J, Johnson-Pais TL, Leach RJ, Liss M, Risinger AL, Sullivan AC, Thompson IM, Morilak DA. Vortioxetine reverses medial prefrontal cortex-mediated cognitive deficits in male rats induced by castration as a model of androgen deprivation therapy for prostate cancer. Psychopharmacology (Berl). 2019 Nov; 236(11):3183-3195. PMID: 31139875.
      Citations: 2     Fields:    Translation:Animals
    39. Goodman PJ, Tangen CM, Thompson IM. More on Long-Term Effects of Finasteride on Prostate Cancer Mortality. Reply. N Engl J Med. 2019 05 16; 380(20):e38. PMID: 31091400.
      Citations:    Fields:    Translation:Humans
    40. Schumacher FR, Olama AAA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA. Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2019 02; 51(2):363. PMID: 30622367.
      Citations: 1     Fields:    
    41. Goodman PJ, Tangen CM, Darke AK, Lucia MS, Ford LG, Minasian LM, Parnes HL, LeBlanc ML, Thompson IM. Long-Term Effects of Finasteride on Prostate Cancer Mortality. N Engl J Med. 2019 01 24; 380(4):393-394. PMID: 30673548.
      Citations: 4     Fields:    Translation:Humans
    42. Newcomb LF, Zheng Y, Faino AV, Bianchi-Frias D, Cooperberg MR, Brown MD, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Liss M, Morgan TM, Thompson IM, Wagner AA, Carroll PR, Nelson PS, Lin DW. Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). Prostate Cancer Prostatic Dis. 2019 09; 22(3):438-445. PMID: 30664734.
      Citations: 9     Fields:    Translation:Humans
    43. Kearns JT, Faino AV, Schenk JM, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner A, Zheng Y, Lin DW. Continued 5a-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS. J Urol. 2019 01; 201(1):106-111. PMID: 30076904.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    44. Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM, Chi KN, Araujo JC, Logothetis C, Quinn DI, Fizazi K, Morris MJ, Eisenberger MA, George DJ, De Bono JS, Higano CS, Tannock IF, Small EJ, Kelly WK. Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. J Clin Oncol. 2019 02 10; 37(5):403-410. PMID: 30576268.
      Citations: 18     Fields:    Translation:Humans
    45. Dai JY, LeBlanc M, Goodman PJ, Lucia MS, Thompson IM, Tangen CM. Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk of High-grade Prostate Cancer by Finasteride. Cancer Prev Res (Phila). 2019 02; 12(2):113-120. PMID: 30538099.
      Citations: 1     Fields:    Translation:Humans
    46. Thompson I, Goodman P, Tangen C. Reduced Risk of Prostate Cancer With 5a-Reductase Inhibitors. J Natl Cancer Inst. 2018 11 01; 110(11):1159-1160. PMID: 29547919.
      Citations:    Fields:    Translation:Humans
    47. Unger JM, Hershman DL, Till C, Tangen CM, Barlow WE, Ramsey SD, Goodman PJ, Thompson IM. Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2018 11 01; 110(11):1208-1215. PMID: 29534197.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    48. Liss MA, Al-Bayati O, Gelfond J, Goros M, Ullevig S, DiGiovanni J, Hamilton-Reeves J, O'Keefe D, Bacich D, Weaver B, Leach R, Thompson IM. Higher baseline dietary fat and fatty acid intake is associated with increased risk of incident prostate cancer in the SABOR study. Prostate Cancer Prostatic Dis. 2019 05; 22(2):244-251. PMID: 30385837.
      Citations: 10     Fields:    Translation:HumansPHPublic Health
    49. Hernandez J, Gelfond J, Goros M, Liss MA, Liang Y, Ankerst D, Thompson IM, Leach RJ. The effect of 3-month finasteride challenge on biomarkers for predicting cancer outcome on biopsy: Results of a randomized trial. PLoS One. 2018; 13(10):e0204823. PMID: 30300367.
      Citations:    Fields:    Translation:Humans
    50. Rivero JR, Thompson IM, Liss MA, Kaushik D. Chemoprevention in Prostate Cancer: Current Perspective and Future Directions. Cold Spring Harb Perspect Med. 2018 10 01; 8(10). PMID: 29311128.
      Citations: 1     Fields:    Translation:Humans
    51. McKiernan J, Donovan MJ, Margolis E, Partin A, Carter B, Brown G, Torkler P, Noerholm M, Skog J, Shore N, Andriole G, Thompson I, Carroll P. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy. Eur Urol. 2018 12; 74(6):731-738. PMID: 30237023.
      Citations: 50     Fields:    Translation:HumansCellsCTClinical Trials
    52. Watts EL, Appleby PN, Perez-Cornago A, Bueno-de-Mesquita HB, Chan JM, Chen C, Cohn BA, Cook MB, Flicker L, Freedman ND, Giles GG, Giovannucci E, Gislefoss RE, Hankey GJ, Kaaks R, Knekt P, Kolonel LN, Kubo T, Le Marchand L, Luben RN, Luostarinen T, Männistö S, Metter EJ, Mikami K, Milne RL, Ozasa K, Platz EA, Quirós JR, Rissanen H, Sawada N, Stampfer M, Stanczyk FZ, Stattin P, Tamakoshi A, Tangen CM, Thompson IM, Tsilidis KK, Tsugane S, Ursin G, Vatten L, Weiss NS, Yeap BB, Allen NE, Key TJ, Travis RC. Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies. Eur Urol. 2018 11; 74(5):585-594. PMID: 30077399.
      Citations: 15     Fields:    Translation:HumansCells
    53. Parekh DJ, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DA, Quek ML, Dash A, Kibel AS, Shemanski L, Pruthi RS, Montgomery JS, Weight CJ, Sharp DS, Chang SS, Cookson MS, Gupta GN, Gorbonos A, Uchio EM, Skinner E, Venkatramani V, Soodana-Prakash N, Kendrick K, Smith JA, Thompson IM. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet. 2018 06 23; 391(10139):2525-2536. PMID: 29976469.
      Citations: 75     Fields:    Translation:HumansCTClinical Trials
    54. Unger JM, Barlow WE, Tangen CM, Ramsey SD, Thompson IM, Klein EA, LeBlanc M, Blanke CD, Goodman PJ, Minasian LM, Nghiem VT, Hershman DL. The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials. Cancer Epidemiol. 2018 08; 55:117-122. PMID: 29936140.
      Citations:    Fields:    Translation:Humans
    55. Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018 07; 50(7):928-936. PMID: 29892016.
      Citations: 167     Fields:    Translation:Humans
    56. Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M, Goh C, Sheng X, Zhang Z, Muir K, Govindasami K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman P, Thompson IM, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger G, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Hakansson N, West C, Dunning AM, Burnet N, Mucci L, Giovannucci E, Andriole G, Cussenot O, Cancel-Tassin G, Koutros S, Freeman LEB, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein B, Kerns S, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Fachal L, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weisher M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Slavov C, Mitev V, Parliament M, Singhal S, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Kierzek A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Kraft P, Freedman M, Wiklund F, Chanock S, Henderson BE, Easton DF, Haiman CA, Eeles RA, Conti DV, Kote-Jarai Z. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nat Commun. 2018 06 11; 9(1):2256. PMID: 29892050.
      Citations: 35     Fields:    Translation:Humans
    57. Liss MA, Rickborn L, DiGiovanni J, Bacich D, DeGraffenried LA, Parihar M, Thompson IM, Sharp ZD. mTOR inhibitors for treatment of low-risk prostate cancer. Med Hypotheses. 2018 Aug; 117:63-68. PMID: 30077200.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    58. Thompson IM. The pendulum swings back: Screening for prostate cancer in 2018. Cancer. 2018 07 01; 124(13):2690-2692. PMID: 29786846.
      Citations:    Fields:    Translation:HumansPHPublic Health
    59. Messing EM, Tangen CM, Lerner SP, Sahasrabudhe DM, Koppie TM, Wood DP, Mack PC, Svatek RS, Evans CP, Hafez KS, Culkin DJ, Brand TC, Karsh LI, Holzbeierlein JM, Wilson SS, Wu G, Plets M, Vogelzang NJ, Thompson IM. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA. 2018 05 08; 319(18):1880-1888. PMID: 29801011.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    60. Hussain M, Tangen CM, Thompson IM, Swanson GP, Wood DP, Sakr W, Dawson NA, Haas NB, Flaig TW, Dorff TB, Lin DW, Crawford ED, Quinn DI, Vogelzang NJ, Glode LM. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol. 2018 05 20; 36(15):1498-1504. PMID: 29624463.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    61. Batth A, Thompson I. Nylon as an in vitro scaffold for three-dimensional study of neural cells. J Biomed Mater Res A. 2018 06; 106(6):1575-1584. PMID: 29430862.
      Citations:    Fields:    Translation:AnimalsCells
    62. Ankerst DP, Goros M, Tomlins SA, Patil D, Feng Z, Wei JT, Sanda MG, Gelfond J, Thompson IM, Leach RJ, Liss MA. Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. Eur Urol Focus. 2019 01; 5(1):54-61. PMID: 29422418.
      Citations: 4     Fields:    Translation:Humans
    63. Kearns JT, Faino AV, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Zheng Y, Lin DW. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. Eur Urol. 2018 05; 73(5):706-712. PMID: 29433973.
      Citations: 2     Fields:    Translation:Humans
    64. Cooperberg MR, Brooks JD, Faino AV, Newcomb LF, Kearns JT, Carroll PR, Dash A, Etzioni R, Fabrizio MD, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Zheng Y. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. Eur Urol. 2018 08; 74(2):211-217. PMID: 29433975.
      Citations: 10     Fields:    Translation:Humans
    65. Tang L, Platek ME, Yao S, Till C, Goodman PJ, Tangen CM, Wu Y, Platz EA, Neuhouser ML, Stanczyk FZ, Reichardt JKV, Santella RM, Hsing A, Figg WD, Lippman SM, Thompson IM, Ambrosone CB. Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Carcinogenesis. 2018 02 09; 39(2):125-133. PMID: 29228205.
      Citations: 3     Fields:    Translation:Humans
    66. Kukreja JB, Thompson IM, Chapin BF. Organizing a clinical trial for the new investigator. Urol Oncol. 2019 05; 37(5):336-339. PMID: 29395953.
      Citations:    Fields:    Translation:Humans
    67. Chu LW, Till C, Yang B, Tangen CM, Goodman PJ, Yu K, Zhu Y, Han S, Hoque AM, Ambrosone C, Thompson I, Leach R, Hsing AW. Circadian genes and risk of prostate cancer in the prostate cancer prevention trial. Mol Carcinog. 2018 03; 57(3):462-466. PMID: 29318656.
      Citations: 3     Fields:    Translation:Humans
    68. Sahoo D, Wei W, Auman H, Hurtado-Coll A, Carroll PR, Fazli L, Gleave ME, Lin DW, Nelson PS, Simko J, Thompson IM, Leach RJ, Troyer DA, True LD, McKenney JK, Feng Z, Brooks JD. Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer. Oncotarget. 2018 Jan 19; 9(5):6550-6561. PMID: 29464091.
      Citations: 5     Fields:    
    69. Liss MA, Thompson IM. Prostate cancer prevention with 5-alpha reductase inhibitors: concepts and controversies. Curr Opin Urol. 2018 Jan; 28(1):42-45. PMID: 29095730.
      Citations: 12     Fields:    Translation:Humans
    70. Twardowski PW, Tangen CM, Wu X, Plets MR, Plimack ER, Agarwal N, Vogelzang NJ, Wang J, Tao S, Thompson IM, Lara P. Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107. Kidney Cancer. 2017 Nov 27; 1(2):123-132. PMID: 30334014.
      Citations: 9     
    71. Thalgott M, Kron M, Brath JM, Ankerst DP, Thompson IM, Gschwend JE, Herkommer K. Men with family history of prostate cancer have a higher risk of disease recurrence after radical prostatectomy. World J Urol. 2018 Feb; 36(2):177-185. PMID: 29164326.
      Citations: 6     Fields:    Translation:Humans
    72. Flaig TW, Plets M, Hussain MHA, Agarwal N, Mitsiades N, Deshpande HA, Vaishampayan UN, Thompson IM. Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol. 2017 Nov 09; 3(11):e170231. PMID: 28358937.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    73. Cheng HH, Plets M, Li H, Higano CS, Tangen CM, Agarwal N, Vogelzang NJ, Hussain M, Thompson IM, Tewari M, Yu EY. Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate. 2018 Feb; 78(2):121-127. PMID: 29105802.
      Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
    74. Ramirez AG, Thompson IM. How will the 'cancer moonshot' impact health disparities? Cancer Causes Control. 2017 Sep; 28(9):907-912. PMID: 28770362.
      Citations: 2     Fields:    Translation:Humans
    75. Sanda MG, Feng Z, Howard DH, Tomlins SA, Sokoll LJ, Chan DW, Regan MM, Groskopf J, Chipman J, Patil DH, Salami SS, Scherr DS, Kagan J, Srivastava S, Thompson IM, Siddiqui J, Fan J, Joon AY, Bantis LE, Rubin MA, Chinnayian AM, Wei JT, Bidair M, Kibel A, Lin DW, Lotan Y, Partin A, Taneja S. Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. JAMA Oncol. 2017 Aug 01; 3(8):1085-1093. PMID: 28520829.
      Citations: 34     Fields:    Translation:Humans
    76. Conti DV, Wang K, Sheng X, Bensen JT, Hazelett DJ, Cook MB, Ingles SA, Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, Stanford JL, Zheng W, Sanderson M, John EM, Park JY, Xu J, Stevens VL, Berndt SI, Huff CD, Wang Z, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Sellers TA, Yamoah K, Murphy AB, Crawford DC, Gapstur SM, Bush WS, Aldrich MC, Cussenot O, Petrovics G, Cullen J, Neslund-Dudas C, Stern MC, Jarai ZK, Govindasami K, Chokkalingam AP, Hsing AW, Goodman PJ, Hoffmann T, Drake BF, Hu JJ, Clark PE, Van Den Eeden SK, Blanchet P, Fowke JH, Casey G, Hennis AJM, Han Y, Lubwama A, Thompson IM, Leach R, Easton DF, Schumacher F, Van den Berg DJ, Gundell SM, Stram A, Wan P, Xia L, Pooler LC, Mohler JL, Fontham ETH, Smith GJ, Taylor JA, Srivastava S, Eeles RA, Carpten J, Kibel AS, Multigner L, Parent ME, Menegaux F, Cancel-Tassin G, Klein EA, Brureau L, Stram DO, Watya S, Chanock SJ, Witte JS, Blot WJ, Henderson BE, Haiman CA. Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. J Natl Cancer Inst. 2017 08 01; 109(8). PMID: 29117387.
      Citations: 24     Fields:    Translation:HumansCells
    77. Platz EA, Kulac I, Barber JR, Drake CG, Joshu CE, Nelson WG, Lucia MS, Klein EA, Lippman SM, Parnes HL, Thompson IM, Goodman PJ, Tangen CM, De Marzo AM. A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts. Cancer Epidemiol Biomarkers Prev. 2017 10; 26(10):1549-1557. PMID: 28754796.
      Citations: 20     Fields:    Translation:Humans
    78. Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara PN, Goldkorn A, Garzotto MG, Mack PC, Higano CS, Vogelzang NJ, Thompson IM, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Quinn DI. Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer. 2017 12; 15(6):635-641. PMID: 28579151.
      Citations: 1     Fields:    Translation:Humans
    79. Long Parma D, Muñoz E, Ogden SM, Westin GF, Leach RJ, Thompson IM, Ramirez AG. Helicobacter Pylori Infection in Texas Hispanic and Non-Hispanic White Men: Implications for Gastric Cancer Risk Disparities. Am J Mens Health. 2017 07; 11(4):1039-1045. PMID: 28413904.
      Citations: 2     Fields:    Translation:HumansCells
    80. Miles FL, Goodman PJ, Tangen C, Torkko KC, Schenk JM, Song X, Pollak M, Thompson IM, Neuhouser ML. Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial. Nutrients. 2017 Apr 12; 9(4). PMID: 28417914.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    81. Winchester DA, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson-Pais TL, Leach RJ, Xu J, Zheng SL, Thompson IM, Lucia MS, Lippman SM, Parnes HL, Isaacs WB, De Marzo AM, Drake CG, Platz EA. Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial. Prostate. 2017 Jun; 77(8):908-919. PMID: 28317149.
      Citations: 5     Fields:    Translation:Humans
    82. Thompson IM. Improved Therapy for PSA Recurrence after Prostatectomy. N Engl J Med. 2017 02 02; 376(5):484-485. PMID: 28146664.
      Citations:    Fields:    Translation:Humans
    83. O'Malley PG, Nguyen DP, Al Hussein Al Awamlh B, Wu G, Thompson IM, Sanda M, Rubin M, Wei JT, Lee R, Christos P, Barbieri C, Scherr DS. Racial Variation in the Utility of Urinary Biomarkers PCA3 and T2ERG in a Large Multicenter Study. J Urol. 2017 07; 198(1):42-49. PMID: 28115190.
      Citations: 2     Fields:    Translation:Humans
    84. Huang G, Osmulski PA, Bouamar H, Mahalingam D, Lin CL, Liss MA, Kumar AP, Chen CL, Thompson IM, Sun LZ, Gaczynska ME, Huang TH. TGF-ß signal rewiring sustains epithelial-mesenchymal transition of circulating tumor cells in prostate cancer xenograft hosts. Oncotarget. 2016 Nov 22; 7(47):77124-77137. PMID: 27780930.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    85. Eminaga O, Wei W, Hawley SJ, Auman H, Newcomb LF, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave ME, Lin DW, Nelson PS, Thompson IM, True LD, McKenney JK, Feng Z, Fazli L, Brooks JD. MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study. PLoS One. 2016; 11(11):e0165236. PMID: 27846218.
      Citations: 9     Fields:    Translation:Humans
    86. McKenney JK, Wei W, Hawley S, Auman H, Newcomb LF, Boyer HD, Fazli L, Simko J, Hurtado-Coll A, Troyer DA, Tretiakova MS, Vakar-Lopez F, Carroll PR, Cooperberg MR, Gleave ME, Lance RS, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, Brooks JD. Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort. Am J Surg Pathol. 2016 11; 40(11):1439-1456. PMID: 27635949.
      Citations: 27     Fields:    Translation:Humans
    87. Macleod LC, Ellis WJ, Newcomb LF, Zheng Y, Brooks JD, Carroll PR, Gleave ME, Lance RS, Nelson PS, Thompson IM, Wagner AA, Wei JT, Lin DW. Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study. J Urol. 2017 04; 197(4):1026-1033. PMID: 27810448.
      Citations: 3     Fields:    Translation:Humans
    88. Tangen CM, Goodman PJ, Till C, Schenk JM, Lucia MS, Thompson IM. Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials. J Clin Oncol. 2016 12 20; 34(36):4338-4344. PMID: 27998216.
      Citations: 17     Fields:    Translation:Humans
    89. Lance P, Alberts DS, Thompson PA, Fales L, Wang F, San Jose J, Jacobs ET, Goodman PJ, Darke AK, Yee M, Minasian L, Thompson IM, Roe DJ. Colorectal Adenomas in Participants of the SELECT Randomized Trial of Selenium and Vitamin E for Prostate Cancer Prevention. Cancer Prev Res (Phila). 2017 Jan; 10(1):45-54. PMID: 27777235.
      Citations: 6     Fields:    Translation:Humans
    90. Esserman LJ, Thompson IM. Laura Esserman and Ian Thompson Discuss Strategies for Screening and Treatment of Early-Stage Cancers, and How Clinicians Can Learn From Each Other's Experiences. Oncology (Williston Park). 2016 09 15; 30(9):770, 785-6. PMID: 27633408.
      Citations:    Fields:    Translation:Humans
    91. Unger JM, Till C, Thompson IM, Tangen CM, Goodman PJ, Wright JD, Barlow WE, Ramsey SD, Minasian LM, Hershman DL. Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2016 12; 108(12). PMID: 27565902.
      Citations: 9     Fields:    Translation:Humans
    92. Crawford ED, Rosenberg MT, Partin AW, Cooperberg MR, Maccini M, Loeb S, Pettaway CA, Shore ND, Arangua P, Hoenemeyer J, Leveridge M, Leapman M, Pinto P, Thompson IM, Carroll P, Eastham J, Gomella L, Klein EA. An Approach Using PSA Levels of 1.5?ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. Urology. 2016 Oct; 96:116-120. PMID: 27450937.
      Citations: 4     Fields:    Translation:Humans
    93. McKiernan J, Donovan MJ, O'Neill V, Bentink S, Noerholm M, Belzer S, Skog J, Kattan MW, Partin A, Andriole G, Brown G, Wei JT, Thompson IM, Carroll P. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. JAMA Oncol. 2016 Jul 01; 2(7):882-9. PMID: 27032035.
      Citations: 158     Fields:    Translation:HumansCells
    94. Kulac I, Gumuskaya B, Drake CG, Gonzalez B, Arnold KB, Goodman PJ, Kristal AR, Lucia MS, Thompson IM, Isaacs WB, De Marzo AM, Platz EA. Peripheral Zone Inflammation Is Not Strongly Associated With Lower Urinary Tract Symptom Incidence and Progression in the Placebo Arm of the Prostate Cancer Prevention Trial?. Prostate. 2016 11; 76(15):1399-408. PMID: 27325488.
      Citations: 3     Fields:    Translation:Humans
    95. Brooks JD, Wei W, Pollack JR, West RB, Shin JH, Sunwoo JB, Hawley SJ, Auman H, Newcomb LF, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave ME, Lin DW, Nelson PS, Thompson IM, True LD, McKenney JK, Feng Z, Fazli L. Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort. Prostate. 2016 11; 76(15):1409-19. PMID: 27325561.
      Citations: 7     Fields:    Translation:Humans
    96. Lotan TL, Wei W, Morais CL, Hawley ST, Fazli L, Hurtado-Coll A, Troyer D, McKenney JK, Simko J, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, Brooks JD. PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer. Eur Urol Focus. 2016 Jun; 2(2):180-188. PMID: 27617307.
      Citations: 18     Fields:    
    97. Chen H, Liu X, Brendler CB, Ankerst DP, Leach RJ, Goodman PJ, Lucia MS, Tangen CM, Wang L, Hsu FC, Sun J, Kader AK, Isaacs WB, Helfand BT, Zheng SL, Thompson IM, Platz EA, Xu J. Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial. Prostate. 2016 09; 76(12):1120-9. PMID: 27197965.
      Citations: 17     Fields:    Translation:Humans
    98. Lotan TL, Wei W, Ludkovski O, Morais CL, Guedes LB, Jamaspishvili T, Lopez K, Hawley ST, Feng Z, Fazli L, Hurtado-Coll A, McKenney JK, Simko J, Carroll PR, Gleave M, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Lance R, Troyer D, Squire JA. Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. Mod Pathol. 2016 08; 29(8):904-14. PMID: 27174589.
      Citations: 25     Fields:    Translation:Humans
    99. Price DK, Chau CH, Till C, Goodman PJ, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Parnes HL, Schenk JM, Tangen CM, Thompson IM, Reichardt JK, Figg WD. Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial. Cancer. 2016 08 01; 122(15):2332-40. PMID: 27164191.
      Citations: 6     Fields:    Translation:Humans
    100. Chan JM, Darke AK, Penney KL, Tangen CM, Goodman PJ, Lee GM, Sun T, Peisch S, Tinianow AM, Rae JM, Klein EA, Thompson IM, Kantoff PW, Mucci LA. Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT. Cancer Epidemiol Biomarkers Prev. 2016 07; 25(7):1050-1058. PMID: 27197287.
      Citations: 10     Fields:    Translation:Humans
    101. Kim J, Davis JW, Klein EA, Magi-Galluzzi C, Lotan Y, Ward JF, Pisters LL, Basler JW, Pettaway CA, Stephenson A, Li Ning Tapia EM, Efstathiou E, Wang X, Do KA, Lee JJ, Gorlov IP, Vornik LA, Hoque AM, Prokhorova IN, Parnes HL, Lippman SM, Thompson IM, Brown PH, Logothetis CJ, Troncoso P. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine. 2016 May; 7:85-93. PMID: 27322462.
      Citations:    Fields:    Translation:Humans
    102. Hershman DL, Unger JM, Wright JD, Ramsey S, Till C, Tangen CM, Barlow WE, Blanke C, Thompson IM, Hussain M. Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer. JAMA Oncol. 2016 Apr; 2(4):453-61. PMID: 26720308.
      Citations: 26     Fields:    Translation:Humans
    103. Wang CP, Lehman DM, Lam YF, Kuhn JG, Mahalingam D, Weitman S, Lorenzo C, Downs JR, Stuart EA, Hernandez J, Thompson IM, Ramirez AG. Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes. Cancer Prev Res (Phila). 2016 Oct; 9(10):779-787. PMID: 27026681.
      Citations: 8     Fields:    Translation:Humans
    104. Ankerst DP, Gelfond J, Goros M, Herrera J, Strobl A, Thompson IM, Hernandez J, Leach RJ. Serial Percent Free Prostate Specific Antigen in Combination with Prostate Specific Antigen for Population Based Early Detection of Prostate Cancer. J Urol. 2016 08; 196(2):355-60. PMID: 26979652.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    105. Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, Vogelzang NJ, Thompson IM, Chi KN, de Bono J, Armstrong AJ, Eisenberger MA, Fandi A, Li S, Araujo JC, Logothetis CJ, Quinn DI, Morris MJ, Higano CS, Tannock IF, Small EJ. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. J Clin Oncol. 2016 05 10; 34(14):1652-9. PMID: 26951312.
      Citations: 92     Fields:    Translation:Humans
    106. Wang Y, Jadhav RR, Liu J, Wilson D, Chen Y, Thompson IM, Troyer DA, Hernandez J, Shi H, Leach RJ, Huang TH, Jin VX. Roles of Distal and Genic Methylation in the Development of Prostate Tumorigenesis Revealed by Genome-wide DNA Methylation Analysis. Sci Rep. 2016 Feb 29; 6:22051. PMID: 26924343.
      Citations: 11     Fields:    Translation:HumansCells
    107. Thompson IM, Ankerst DP. The Role of Magnetic Resonance Imaging in Prostate Cancer: Focusing on What Really Matters. Eur Urol. 2016 10; 70(4):574-575. PMID: 26861475.
      Citations:    Fields:    Translation:Humans
    108. Winchester DA, Gurel B, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson-Pais TL, Leach RJ, Thompson IM, Xu J, Zheng SL, Lucia MS, Lippman SM, Parnes HL, Isaacs WB, Drake CG, De Marzo AM, Platz EA. Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial. Prostate. 2016 May; 76(6):565-74. PMID: 26771888.
      Citations: 2     Fields:    Translation:Humans
    109. Brawley OW, Thompson IM, Grönberg H. Evolving Recommendations on Prostate Cancer Screening. Am Soc Clin Oncol Educ Book. 2016; 35:e80-7. PMID: 27249774.
      Citations: 5     Fields:    Translation:Humans
    110. Murtola TJ, Gurel B, Umbehr M, Lucia MS, Thompson IM, Goodman PJ, Kristal AR, Parnes HL, Lippman SM, Sutcliffe S, Peskoe SB, Barber JR, Drake CG, Nelson WG, De Marzo AM, Platz EA. Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2016 Mar; 25(3):463-9. PMID: 26715424.
      Citations: 7     Fields:    Translation:Humans
    111. Schenk JM, Till C, Hsing AW, Stanczyk FZ, Gong Z, Neuhouser ML, Reichardt JK, Hoque AM, Figg WD, Goodman PJ, Tangen CM, Thompson IM. Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial. Cancer Causes Control. 2016 Feb; 27(2):175-82. PMID: 26589415.
      Citations: 11     Fields:    Translation:Humans
    112. Hussain M, Tangen C, Higano C, Vogelzang N, Thompson I. Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details. J Clin Oncol. 2016 Jan 20; 34(3):280-5. PMID: 26552421.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    113. Ankerst DP, Liss M, Zapata D, Hoefler J, Thompson IM, Leach RJ. A case control study of sarcosine as an early prostate cancer detection biomarker. BMC Urol. 2015 Oct 01; 15:99. PMID: 26429735.
      Citations: 8     Fields:    Translation:Humans
    114. Horning AM, Awe JA, Wang CM, Liu J, Lai Z, Wang VY, Jadhav RR, Louie AD, Lin CL, Kroczak T, Chen Y, Jin VX, Abboud-Werner SL, Leach RJ, Hernandez J, Thompson IM, Saranchuk J, Drachenberg D, Chen CL, Mai S, Huang TH. DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence. Prostate. 2015 Nov; 75(15):1790-801. PMID: 26332453.
      Citations: 10     Fields:    Translation:HumansCells
    115. Newcomb LF, Thompson IM, Boyer HD, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Ellis WJ, Fazli L, Feng Z, Gleave ME, Kunju P, Lance RS, McKenney JK, Meng MV, Nicolas MM, Sanda MG, Simko J, So A, Tretiakova MS, Troyer DA, True LD, Vakar-Lopez F, Virgin J, Wagner AA, Wei JT, Zheng Y, Nelson PS, Lin DW. Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. J Urol. 2016 Feb; 195(2):313-20. PMID: 26327354.
      Citations: 48     Fields:    Translation:HumansPHPublic Health
    116. Morales EE, Grill S, Svatek RS, Kaushik D, Thompson IM, Ankerst DP, Liss MA. Finasteride Reduces Risk of Bladder Cancer in a Large Prospective Screening Study. Eur Urol. 2016 Mar; 69(3):407-10. PMID: 26320383.
      Citations: 15     Fields:    Translation:Humans
    117. Nash SH, Till C, Song X, Lucia MS, Parnes HL, Thompson IM, Lippman SM, Platz EA, Schenk J. Serum Retinol and Carotenoid Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2015 Oct; 24(10):1507-15. PMID: 26269564.
      Citations: 9     Fields:    Translation:Humans
    118. Brath JM, Grill S, Ankerst DP, Thompson IM, Gschwend JE, Herkommer K. No Detrimental Effect of a Positive Family History on Long-Term Outcomes Following Radical Prostatectomy. J Urol. 2016 Feb; 195(2):343-8. PMID: 26239337.
      Citations: 5     Fields:    Translation:Humans
    119. Brooks JD, Wei W, Hawley S, Auman H, Newcomb L, Boyer H, Fazli L, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, McKenney JK. Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients. PLoS One. 2015; 10(7):e0132343. PMID: 26172920.
      Citations: 15     Fields:    Translation:Humans
    120. Folsom AR, Yao L, Alonso A, Lutsey PL, Missov E, Lederle FA, Ballantyne CM, Tang W. Circulating Biomarkers and Abdominal Aortic Aneurysm Incidence: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2015 Aug 18; 132(7):578-85. PMID: 16988157.
      Citations: 7     Fields:    Translation:Humans
    121. Folsom AR, Yao L, Alonso A, Lutsey PL, Missov E, Lederle FA, Ballantyne CM, Tang W. Circulating Biomarkers and Abdominal Aortic Aneurysm Incidence: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2015 Aug 18; 132(7):578-85. PMID: 27889277.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    122. Winchester DA, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson-Pais TL, Leach RJ, Xu J, Zheng SL, Thompson IM, Lucia MS, Lippmann SM, Parnes HL, Dluzniewski PJ, Isaacs WB, De Marzo AM, Drake CG, Platz EA. Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial. Prostate. 2015 Sep; 75(13):1403-18. PMID: 26047319.
      Citations: 17     Fields:    Translation:Humans
    123. Figg WD, Thompson IM. Effect of 5a-Reductase Inhibitor Use on Mortality From Prostate Cancer. JAMA Oncol. 2015 Jun; 1(3):321-2. PMID: 26181178.
      Citations: 3     Fields:    Translation:Humans
    124. Barrington WE, Schenk JM, Etzioni R, Arnold KB, Neuhouser ML, Thompson IM, Lucia MS, Kristal AR. Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA Oncol. 2015 Jun; 1(3):342-9. PMID: 26181184.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    125. Strobl AN, Vickers AJ, Van Calster B, Steyerberg E, Leach RJ, Thompson IM, Ankerst DP. Improving patient prostate cancer risk assessment: Moving from static, globally-applied to dynamic, practice-specific risk calculators. J Biomed Inform. 2015 Aug; 56:87-93. PMID: 25989018.
      Citations: 9     Fields:    Translation:Humans
    126. Chau CH, Price DK, Till C, Goodman PJ, Chen X, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Tangen CM, Chu L, Parnes HL, Schenk JM, Reichardt JK, Thompson IM, Figg WD. Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial. PLoS One. 2015; 10(5):e0126672. PMID: 25955319.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    127. Troyer DA, Jamaspishvili T, Wei W, Feng Z, Good J, Hawley S, Fazli L, McKenney JK, Simko J, Hurtado-Coll A, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Squire JA. A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate. 2015 Aug 01; 75(11):1206-15. PMID: 25939393.
      Citations: 25     Fields:    Translation:Humans
    128. Nash SH, Schenk JM, Kristal AR, Goodman PJ, Lucia MS, Parnes HL, Thompson IM, Lippman SM, Song X, Gurel B, De Marzo A, Platz EA. Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila). 2015 Jul; 8(7):590-6. PMID: 25926387.
      Citations: 4     Fields:    Translation:Humans
    129. Liu B, Dhanda A, Hirani S, Williams EL, Sen HN, Martinez Estrada F, Ling D, Thompson I, Casady M, Li Z, Si H, Tucker W, Wei L, Jawad S, Sura A, Dailey J, Hannes S, Chen P, Chien JL, Gordon S, Lee RW, Nussenblatt RB. CD14++CD16+ Monocytes Are Enriched by Glucocorticoid Treatment and Are Functionally Attenuated in Driving Effector T Cell Responses. J Immunol. 2015 Jun 01; 194(11):5150-60. PMID: 25911752.
      Citations: 26     Fields:    Translation:HumansCells
    130. Heaphy CM, Gaonkar G, Peskoe SB, Joshu CE, De Marzo AM, Lucia MS, Goodman PJ, Lippman SM, Thompson IM, Platz EA, Meeker AK. Prostate stromal cell telomere shortening is associated with risk of prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial. Prostate. 2015 Aug 01; 75(11):1160-6. PMID: 25893825.
      Citations: 9     Fields:    Translation:HumansCells
    131. Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang NJ, Quinn DI, Cheng HH, Plymate SR, Hussain M, Tangen CM, Thompson IM. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2015 May 10; 33(14):1601-8. PMID: 25847934.
      Citations: 22     Fields:    Translation:HumansCellsCTClinical Trials
    132. Ankerst DP, Xia J, Thompson IM, Hoefler J, Newcomb LF, Brooks JD, Carroll PR, Ellis WJ, Gleave ME, Lance RS, Nelson PS, Wagner AA, Wei JT, Etzioni R, Lin DW. Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator. Eur Urol. 2015 Dec; 68(6):1083-8. PMID: 25819722.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    133. Hoque A, Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, Reichardt JK, vanBokhoven A, Neuhouser ML, Santella RM, Figg WD, Price DK, Parnes HL, Lippman SM, Ambrosone CB, Thompson IM. Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease. Urology. 2015 Mar; 85(3):616-20. PMID: 25733274.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    134. Milly H, Festy F, Andiappan M, Watson TF, Thompson I, Banerjee A. Surface pre-conditioning with bioactive glass air-abrasion can enhance enamel white spot lesion remineralization. Dent Mater. 2015 May; 31(5):522-33. PMID: 25735757.
      Citations: 4     Fields:    Translation:Humans
    135. Gelfond J, Choate K, Ankerst DP, Hernandez J, Leach RJ, Thompson IM. Intermediate-Term Risk of Prostate Cancer is Directly Related to Baseline Prostate Specific Antigen: Implications for Reducing the Burden of Prostate Specific Antigen Screening. J Urol. 2015 Jul; 194(1):46-51. PMID: 25686543.
      Citations: 5     Fields:    Translation:Humans
    136. Strobl AN, Thompson IM, Vickers AJ, Ankerst DP. The Next Generation of Clinical Decision Making Tools: Development of a Real-Time Prediction Tool for Outcome of Prostate Biopsy in Response to a Continuously Evolving Prostate Cancer Landscape. J Urol. 2015 Jul; 194(1):58-64. PMID: 25636656.
      Citations: 4     Fields:    Translation:Humans
    137. Overholser S, Nielsen M, Torkko K, Cwilka D, Weaver B, Shi X, Leach RJ, Hernandez J, Huang T, Thompson IM, Thompson IM. Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing. J Urol. 2015 Sep; 194(3):680-4. PMID: 25636657.
      Citations: 9     Fields:    Translation:Humans
    138. Christen WG, Glynn RJ, Gaziano JM, Darke AK, Crowley JJ, Goodman PJ, Lippman SM, Lad TE, Bearden JD, Goodman GE, Minasian LM, Thompson IM, Blanke CD, Klein EA. Age-related cataract in men in the selenium and vitamin e cancer prevention trial eye endpoints study: a randomized clinical trial. JAMA Ophthalmol. 2015 Jan; 133(1):17-24. PMID: 25232809.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    139. Wei JT, Feng Z, Partin AW, Brown E, Thompson I, Sokoll L, Chan DW, Lotan Y, Kibel AS, Busby JE, Bidair M, Lin DW, Taneja SS, Viterbo R, Joon AY, Dahlgren J, Kagan J, Srivastava S, Sanda MG. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol. 2014 Dec 20; 32(36):4066-72. PMID: 25385735.
      Citations: 98     Fields:    Translation:Humans
    140. Sutcliffe S, Till C, Jenkins FJ, Gaydos CA, Goodman PJ, Hoque AM, Hsing AW, Thompson IM, Nelson WG, De Marzo AM, Platz EA. Prospective study of human herpesvirus type 8 serostatus and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial. Cancer Causes Control. 2015 Jan; 26(1):35-44. PMID: 25359302.
      Citations: 4     Fields:    Translation:HumansCells
    141. Goldkorn A, Ely B, Tangen CM, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Vogelzang NJ, Thompson IM, Cote RJ, Quinn DI. Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer. 2015 Apr 15; 136(8):1856-62. PMID: 25219358.
      Citations: 24     Fields:    Translation:HumansCellsCTClinical Trials
    142. Grill S, Fallah M, Leach RJ, Thompson IM, Freedland S, Hemminki K, Ankerst DP. Incorporation of detailed family history from the Swedish Family Cancer Database into the PCPT risk calculator. J Urol. 2015 Feb; 193(2):460-5. PMID: 25242395.
      Citations: 10     Fields:    Translation:Humans
    143. Thompson IM, Leach RJ, Ankerst DP. Focusing PSA testing on detection of high-risk prostate cancers by incorporating patient preferences into decision making. JAMA. 2014 Sep 10; 312(10):995-6. PMID: 25090603.
      Citations: 15     Fields:    Translation:Humans
    144. Jarow JP, Thompson IM. Reply by the authors. Urology. 2014 Sep; 84(3):733. PMID: 25168561.
      Citations:    Fields:    Translation:Humans
    145. Thompson IM, Tangen CM. Prostate cancer screening comes of age. Lancet. 2014 Dec 06; 384(9959):2004-6. PMID: 25108887.
      Citations: 5     Fields:    Translation:Humans
    146. Osmulski P, Mahalingam D, Gaczynska ME, Liu J, Huang S, Horning AM, Wang CM, Thompson IM, Huang TH, Chen CL. Nanomechanical biomarkers of single circulating tumor cells for detection of castration resistant prostate cancer. Prostate. 2014 Sep; 74(13):1297-307. PMID: 25065737.
      Citations: 16     Fields:    Translation:HumansCells
    147. Mosquera-Lopez C, Agaian S, Velez-Hoyos A, Thompson I. Computer-Aided Prostate Cancer Diagnosis From Digitized Histopathology: A Review on Texture-Based Systems. IEEE Rev Biomed Eng. 2015; 8:98-113. PMID: 25055385.
      Citations: 14     Fields:    Translation:Humans
    148. Gritz ER, Arnold KB, Moinpour CM, Burton-Chase AM, Tangen CM, Probstfield JF, See WA, Lieber MM, Caggiano V, Moody-Thomas S, Szczepanek C, Ryan A, Carlin S, Hill S, Goodman PJ, Padberg RM, Minasian LM, Meyskens FL, Thompson IM. Factors associated with adherence to an end-of-study biopsy: lessons from the prostate cancer prevention trial (SWOG-Coordinated Intergroup Study S9217). Cancer Epidemiol Biomarkers Prev. 2014 Aug; 23(8):1638-48. PMID: 25028457.
      Citations: 3     Fields:    Translation:Humans
    149. Albanes D, Till C, Klein EA, Goodman PJ, Mondul AM, Weinstein SJ, Taylor PR, Parnes HL, Gaziano JM, Song X, Fleshner NE, Brown PH, Meyskens FL, Thompson IM. Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Prev Res (Phila). 2014 Sep; 7(9):886-95. PMID: 24961880.
      Citations: 19     Fields:    Translation:Humans
    150. Ankerst DP, Hoefler J, Bock S, Goodman PJ, Vickers A, Hernandez J, Sokoll LJ, Sanda MG, Wei JT, Leach RJ, Thompson IM. Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology. 2014 Jun; 83(6):1362-7. PMID: 24862395.
      Citations: 60     Fields:    Translation:HumansPHPublic Health
    151. Ankerst DP, Thompson IM. Reply: To PMID 24862395. Urology. 2014 Jun; 83(6):1368. PMID: 24862397.
      Citations:    Fields:    Translation:Humans
    152. Parra A, Karnad AB, Thompson IM. Hispanic accrual on randomized cancer clinical trials: a call to arms. J Clin Oncol. 2014 Jun 20; 32(18):1871-3. PMID: 24841978.
      Citations: 10     Fields:    Translation:Humans
    153. Figg WD, Chau CH, Price DK, Till C, Goodman PJ, Cho Y, Varella-Garcia M, Reichardt JK, Tangen CM, Leach RJ, van Bokhoven A, Thompson IM, Lucia MS. Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results From the Prostate Cancer Prevention Trial. Urology. 2014 Jul; 84(1):127-31. PMID: 24824408.
      Citations: 5     Fields:    Translation:HumansCells
    154. Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch HG, Hwang S, Berry DA, Kinzler KW, Black WC, Bissell M, Parnes H, Srivastava S. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol. 2014 May; 15(6):e234-42. PMID: 24807866.
      Citations: 124     Fields:    Translation:Humans
    155. Thompson IM, Tangen CM, Goodman PJ. Re: Long-term survival of participants in the Prostate Cancer Prevention Trial. Asian J Androl. 2014 May-Jun; 16(3):414. PMID: 24914438.
      Citations:    Fields:    Translation:Humans
    156. Liang Y, Ketchum NS, Goodman PJ, Klein EA, Thompson IM. Is there a role for body mass index in the assessment of prostate cancer risk on biopsy? J Urol. 2014 Oct; 192(4):1094-9. PMID: 24747090.
      Citations: 6     Fields:    Translation:Humans
    157. Hsing AW, Yeboah E, Biritwum R, Tettey Y, De Marzo AM, Adjei A, Netto GJ, Yu K, Li Y, Chokkalingam AP, Chu LW, Chia D, Partin A, Thompson IM, Quraishi SM, Niwa S, Tarone R, Hoover RN. High prevalence of screen detected prostate cancer in West Africans: implications for racial disparity of prostate cancer. J Urol. 2014 Sep; 192(3):730-5. PMID: 24747091.
      Citations: 23     Fields:    Translation:Humans
    158. Gurel B, Lucia MS, Thompson IM, Goodman PJ, Tangen CM, Kristal AR, Parnes HL, Hoque A, Lippman SM, Sutcliffe S, Peskoe SB, Drake CG, Nelson WG, De Marzo AM, Platz EA. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2014 May; 23(5):847-56. PMID: 24748218.
      Citations: 93     Fields:    Translation:Humans
    159. Kristal AR, Till C, Song X, Tangen CM, Goodman PJ, Neuhauser ML, Schenk JM, Thompson IM, Meyskens FL, Goodman GE, Minasian LM, Parnes HL, Klein EA. Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2014 Aug; 23(8):1494-504. PMID: 24732629.
      Citations: 36     Fields:    Translation:Humans
    160. Brasky TM, Thompson IM, King IB, Kristal AR. Response. J Natl Cancer Inst. 2014 Apr; 106(4):dju021. PMID: 24685927.
      Citations: 2     Fields:    Translation:Humans
    161. Jarow JP, Thompson IM, Kluetz PG, Baxley J, Sridhara R, Scardino P, Carroll P, Albertsen P, Carter HB, Brawley O, Sartor O, Sandler H, Kiefert JJ, Morton RA. Drug and device development for localized prostate cancer: report of a Food and Drug Administration/American Urological Association public workshop. Urology. 2014 May; 83(5):975-8. PMID: 24661332.
      Citations: 5     Fields:    Translation:Humans
    162. Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Datar RH, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Thompson IM, Cote RJ, Vogelzang NJ. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol. 2014 Apr 10; 32(11):1136-42. PMID: 24616308.
      Citations: 110     Fields:    Translation:HumansCellsCTClinical Trials
    163. Vickers AJ, Thompson IM, Klein E, Carroll PR, Scardino PT. A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer. Urology. 2014 Mar; 83(3):592-6. PMID: 24581521.
      Citations: 17     Fields:    Translation:Humans
    164. Lara PN, Ely B, Quinn DI, Mack PC, Tangen C, Gertz E, Twardowski PW, Goldkorn A, Hussain M, Vogelzang NJ, Thompson IM, Van Loan MD. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. J Natl Cancer Inst. 2014 Apr; 106(4):dju013. PMID: 24565955.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    165. Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL, Goodman GE, Minasian LM, Parnes HL, Lippman SM, Klein EA. Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst. 2014 Mar; 106(3):djt456. PMID: 24563519.
      Citations: 71     Fields:    Translation:Humans
    166. Etzioni RD, Thompson IM. What do the screening trials really tell us and where do we go from here? Urol Clin North Am. 2014 May; 41(2):223-8. PMID: 24725484.
      Citations: 7     Fields:    Translation:HumansPHPublic Health
    167. Vickers AJ, Sjoberg DD, Ulmert D, Vertosick E, Roobol MJ, Thompson I, Heijnsdijk EA, De Koning H, Atoria-Swartz C, Scardino PT, Lilja H. Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. BMC Med. 2014 Feb 11; 12:26. PMID: 24512643.
      Citations: 30     Fields:    Translation:HumansPHPublic Health
    168. Platz EA, Tangen CM, Goodman PJ, Till C, Parnes HL, Figg WD, Albanes D, Neuhouser ML, Klein EA, Lucia MS, Thompson IM, Kristal AR. Statin drug use is not associated with prostate cancer risk in men who are regularly screened. J Urol. 2014 Aug; 192(2):379-84. PMID: 24518774.
      Citations: 20     Fields:    Translation:Humans
    169. Esserman LJ, Thompson IM, Reid BJ. Changing the terminology of cancer--reply. JAMA. 2014 Jan 08; 311(2):203. PMID: 24399568.
      Citations:    Fields:    Translation:Humans
    170. Leake JL, Hardman R, Ojili V, Thompson I, Shanbhogue A, Hernandez J, Barentsz J. Prostate MRI: access to and current practice of prostate MRI in the United States. J Am Coll Radiol. 2014 Feb; 11(2):156-60. PMID: 24389134.
      Citations: 7     Fields:    Translation:Humans
    171. Thompson I, Kristal A, Platz EA. Prevention of prostate cancer: outcomes of clinical trials and future opportunities. Am Soc Clin Oncol Educ Book. 2014; e76-80. PMID: 24857150.
      Citations: 4     Fields:    Translation:Humans
    172. Chen-Pin W, Javier H, Lorenzo C, Downs JR, Thompson IM, Pollock B, Lehman D. Statins and Finasteride Use Differentially Modify the Impact of Metformin on Prostate Cancer Incidence in Men with Type 2 Diabetes. Ann Transl Med Epidemiol. 2014; 1(1). PMID: 25621309.
      Citations: 4     
    173. Patel JD, Krilov L, Adams S, Aghajanian C, Basch E, Brose MS, Carroll WL, de Lima M, Gilbert MR, Kris MG, Marshall JL, Masters GA, O'Day SJ, Polite B, Schwartz GK, Sharma S, Thompson I, Vogelzang NJ, Roth BJ. Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol. 2014 Jan 10; 32(2):129-60. PMID: 24327669.
      Citations: 31     Fields:    Translation:Humans
    174. Medina EA, Shi X, Grayson MH, Ankerst DP, Livi CB, Medina MV, Thompson IM, Leach RJ. The diagnostic value of adiponectin multimers in healthy men undergoing screening for prostate cancer. Cancer Epidemiol Biomarkers Prev. 2014 Feb; 23(2):309-15. PMID: 24296854.
      Citations: 4     Fields:    Translation:Humans
    175. Thompson IM, Cabang AB, Wargovich MJ. Future directions in the prevention of prostate cancer. Nat Rev Clin Oncol. 2014 Jan; 11(1):49-60. PMID: 24281061.
      Citations: 16     Fields:    Translation:HumansPHPublic Health
    176. Milly H, Festy F, Watson TF, Thompson I, Banerjee A. Enamel white spot lesions can remineralise using bio-active glass and polyacrylic acid-modified bio-active glass powders. J Dent. 2014 Feb; 42(2):158-66. PMID: 24287257.
      Citations: 9     Fields:    Translation:Humans
    177. Tangen CM, Goodman PJ, Thompson IM. Survival in the prostate cancer prevention trial. N Engl J Med. 2013 11 14; 369(20):1968. PMID: 24224632.
      Citations:    Fields:    Translation:Humans
    178. Ramsey SD, Zeliadt SB, Blough DK, Moinpour CM, Hall IJ, Smith JL, Ekwueme DU, Fedorenko CR, Fairweather ME, Koepl LM, Thompson IM, Keane TE, Penson DF. Impact of prostate cancer on sexual relationships: a longitudinal perspective on intimate partners' experiences. J Sex Med. 2013 Dec; 10(12):3135-43. PMID: 24118980.
      Citations: 14     Fields:    Translation:Humans
    179. Hsu YT, Gu F, Huang YW, Liu J, Ruan J, Huang RL, Wang CM, Chen CL, Jadhav RR, Lai HC, Mutch DG, Goodfellow PJ, Thompson IM, Kirma NB, Huang TH. Promoter hypomethylation of EpCAM-regulated bone morphogenetic protein gene family in recurrent endometrial cancer. Clin Cancer Res. 2013 Nov 15; 19(22):6272-85. PMID: 24077349.
      Citations: 21     Fields:    Translation:HumansCells
    180. Ankerst DP, Till C, Boeck A, Goodman PJ, Tangen CM, Thompson IM. Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and American Urological Association symptom score. Urology. 2013 Nov; 82(5):1076-81. PMID: 24055241.
      Citations: 3     Fields:    Translation:Humans
    181. Blackburn A, Wilson D, Gelfond J, Yao L, Hernandez J, Thompson IM, Leach RJ, Lehman DM. Validation of copy number variants associated with prostate cancer risk and prognosis. Urol Oncol. 2014 Jan; 32(1):44.e15-44.e20. PMID: 24054869.
      Citations: 1     Fields:    Translation:HumansCells
    182. Trevino M, Padalecki S, Karnad A, Parra A, Weitman S, Nashawati M, Pollock BH, Ramirez A, Thompson IM. The Development of a Minority Recruitment Plan for Cancer Clinical Trials. J Community Med Health Educ. 2013 Sep 01; 3(5):1000230. PMID: 25152846.
      Citations: 4     
    183. Esserman LJ, Thompson IM, Reid B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA. 2013 Aug 28; 310(8):797-8. PMID: 23896967.
      Citations: 138     Fields:    Translation:Humans
    184. Li C, Zeliadt SB, Hall IJ, Smith JL, Ekwueme DU, Moinpour CM, Penson DF, Thompson IM, Keane TE, Ramsey SD. Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspective. Support Care Cancer. 2013 Dec; 21(12):3461-9. PMID: 23955026.
      Citations: 14     Fields:    Translation:Humans
    185. Thompson IM, Goodman PJ, Tangen CM, Parnes HL, Minasian LM, Godley PA, Lucia MS, Ford LG. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med. 2013 Aug 15; 369(7):603-10. PMID: 23944298.
      Citations: 83     Fields:    Translation:Humans
    186. Hsu PY, Hsu HK, Lan X, Juan L, Yan PS, Labanowska J, Heerema N, Hsiao TH, Chiu YC, Chen Y, Liu Y, Li L, Li R, Thompson IM, Nephew KP, Sharp ZD, Kirma NB, Jin VX, Huang TH. Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer. Cancer Cell. 2013 Aug 12; 24(2):197-212. PMID: 23948299.
      Citations: 34     Fields:    Translation:HumansCells
    187. Valicenti RK, Thompson I, Albertsen P, Davis BJ, Goldenberg SL, Wolf JS, Sartor O, Klein E, Hahn C, Michalski J, Roach M, Faraday MM. Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. Int J Radiat Oncol Biol Phys. 2013 Aug 01; 86(5):822-8. PMID: 23845839.
      Citations: 49     Fields:    Translation:Humans
    188. Quinn DI, Tangen CM, Hussain M, Lara PN, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol. 2013 Aug; 14(9):893-900. PMID: 23871417.
      Citations: 64     Fields:    Translation:HumansCTClinical Trials
    189. Brasky TM, Darke AK, Song X, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL, Goodman GE, Minasian LM, Parnes HL, Klein EA, Kristal AR. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst. 2013 Aug 07; 105(15):1132-41. PMID: 23843441.
      Citations: 84     Fields:    Translation:Humans
    190. Schenk JM, Hunter-Merrill R, Zheng Y, Etzioni R, Gulati R, Tangen C, Thompson IM, Kristal AR. Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia? Am J Epidemiol. 2013 Sep 01; 178(5):741-51. PMID: 23813705.
      Citations: 1     Fields:    Translation:Humans
    191. Vickers AJ, Sjoberg DD, Ankerst DP, Tangen CM, Goodman PJ, Thompson IM. The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome. Cancer. 2013 Aug 15; 119(16):3007-11. PMID: 23720006.
      Citations: 8     Fields:    Translation:Humans
    192. Thompson IM, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C, Klein E, Michalski J, Roach M, Sartor O, Wolf JS, Faraday MM. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol. 2013 Aug; 190(2):441-9. PMID: 23707439.
      Citations: 106     Fields:    Translation:Humans
    193. Huang RL, Gu F, Kirma NB, Ruan J, Chen CL, Wang HC, Liao YP, Chang CC, Yu MH, Pilrose JM, Thompson IM, Huang HC, Huang TH, Lai HC, Nephew KP. Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers. Epigenetics. 2013 Jun; 8(6):624-34. PMID: 23774800.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    194. Skinner EC, Goldman B, Sakr WA, Petrylak DP, Lenz HJ, Lee CT, Wilson SS, Benson M, Lerner SP, Tangen CM, Thompson IM. SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin. J Urol. 2013 Oct; 190(4):1200-4. PMID: 23597452.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    195. Huang TT, Gonzales CB, Gu F, Hsu YT, Jadhav RR, Wang CM, Redding SW, Tseng CE, Lee CC, Thompson IM, Chen HR, Huang TH, Kirma NB. Epigenetic deregulation of the anaplastic lymphoma kinase gene modulates mesenchymal characteristics of oral squamous cell carcinomas. Carcinogenesis. 2013 Aug; 34(8):1717-27. PMID: 23568951.
      Citations: 12     Fields:    Translation:HumansCells
    196. Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013 Apr 04; 368(14):1314-25. PMID: 23550669.
      Citations: 137     Fields:    Translation:Humans
    197. Etzioni R, Gulati R, Cooperberg MR, Penson DM, Weiss NS, Thompson IM. Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening. Med Care. 2013 Apr; 51(4):295-300. PMID: 23269114.
      Citations: 20     Fields:    Translation:Humans
    198. Lin DW, Newcomb LF, Brown EC, Brooks JD, Carroll PR, Feng Z, Gleave ME, Lance RS, Sanda MG, Thompson IM, Wei JT, Nelson PS. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res. 2013 May 01; 19(9):2442-50. PMID: 23515404.
      Citations: 54     Fields:    Translation:Humans
    199. Rebbeck TR, Devesa SS, Chang BL, Bunker CH, Cheng I, Cooney K, Eeles R, Fernandez P, Giri VN, Gueye SM, Haiman CA, Henderson BE, Heyns CF, Hu JJ, Ingles SA, Isaacs W, Jalloh M, John EM, Kibel AS, Kidd LR, Layne P, Leach RJ, Neslund-Dudas C, Okobia MN, Ostrander EA, Park JY, Patrick AL, Phelan CM, Ragin C, Roberts RA, Rybicki BA, Stanford JL, Strom S, Thompson IM, Witte J, Xu J, Yeboah E, Hsing AW, Zeigler-Johnson CM. Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. Prostate Cancer. 2013; 2013:560857. PMID: 23476788.
      Citations: 77     
    200. Neuhouser ML, Platz EA, Till C, Tangen CM, Goodman PJ, Kristal A, Parnes HL, Tao Y, Figg WD, Lucia MS, Hoque A, Hsing AW, Thompson IM, Pollak M. Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial. Cancer Prev Res (Phila). 2013 Feb; 6(2):91-9. PMID: 23315596.
      Citations: 18     Fields:    Translation:Humans
    201. Ankerst DP, Till C, Boeck A, Goodman P, Tangen CM, Feng Z, Partin AW, Chan DW, Sokoll L, Kagan J, Wei JT, Thompson IM. The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator. J Urol. 2013 Jul; 190(1):70-6. PMID: 23313212.
      Citations: 16     Fields:    Translation:Humans
    202. Thompson IM, Leach R. Prostate cancer and prostatic intraepithelial neoplasia: true, true, and unrelated? J Clin Oncol. 2013 Feb 10; 31(5):515-6. PMID: 23295801.
      Citations: 2     Fields:    Translation:Humans
    203. Hawley S, Fazli L, McKenney JK, Simko J, Troyer D, Nicolas M, Newcomb LF, Cowan JE, Crouch L, Ferrari M, Hernandez J, Hurtado-Coll A, Kuchinsky K, Liew J, Mendez-Meza R, Smith E, Tenggara I, Zhang X, Carroll PR, Chan JM, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, Feng Z, True LD, Brooks JD. A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray. Adv Anat Pathol. 2013 Jan; 20(1):39-44. PMID: 23232570.
      Citations: 12     Fields:    Translation:Humans
    204. Chen CL, Mahalingam D, Osmulski P, Jadhav RR, Wang CM, Leach RJ, Chang TC, Weitman SD, Kumar AP, Sun L, Gaczynska ME, Thompson IM, Huang TH. Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer. Prostate. 2013 Jun; 73(8):813-26. PMID: 23280481.
      Citations: 95     Fields:    Translation:HumansCells
    205. Hilton WM, Padalecki SS, Ankerst DP, Leach RJ, Thompson IM. Temporal changes in the clinical approach to diagnosing prostate cancer. J Natl Cancer Inst Monogr. 2012 Dec; 2012(45):162-8. PMID: 23271768.
      Citations: 2     Fields:    Translation:Humans
    206. Feng Z, Kagan J, Pepe M, Thornquist M, Ann Rinaudo J, Dahlgren J, Krueger K, Zheng Y, Patriotis C, Huang Y, Sorbara L, Thompson I, Srivastava S. The Early Detection Research Network's Specimen reference sets: paving the way for rapid evaluation of potential biomarkers. Clin Chem. 2013 Jan; 59(1):68-74. PMID: 23193062.
      Citations: 20     Fields:    Translation:Humans
    207. Bedolla RG, Gong J, Prihoda TJ, Yeh IT, Thompson IM, Ghosh R, Kumar AP. Predictive value of Sp1/Sp3/FLIP signature for prostate cancer recurrence. PLoS One. 2012; 7(9):e44917. PMID: 23028678.
      Citations: 11     Fields:    Translation:Humans
    208. Moinpour CM, Darke AK, Donaldson GW, Cespedes D, Johnson CR, Ganz PA, Patrick DL, Ware JE, Shumaker SA, Meyskens FL, Thompson IM. Health-related quality-of-life findings for the prostate cancer prevention trial. J Natl Cancer Inst. 2012 Sep 19; 104(18):1373-85. PMID: 22972968.
      Citations: 8     Fields:    Translation:Humans
    209. Nam RK, Oliver TK, Vickers AJ, Thompson I, Kantoff PW, Parnes HL, Loblaw A, Roth BJ, Williams J, Temin S, Basch E. Prostate-specific antigen test for prostate cancer screening: American Society of Clinical Oncology provisional clinical opinion. J Oncol Pract. 2012 Sep; 8(5):315-7. PMID: 23277770.
      Citations: 4     Fields:    Translation:Humans
    210. Tangen CM, Hussain MH, Higano CS, Eisenberger MA, Small EJ, Wilding G, Donnelly BJ, Schelhammer PF, Crawford ED, Vogelzang NJ, Powell IJ, Thompson IM. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol. 2012 Oct; 188(4):1164-9. PMID: 22921015.
      Citations: 30     Fields:    Translation:Humans
    211. Klotz L, Thompson I. Re: Active surveillance versus surgery for low risk prostate cancer: a clinical decision analysis: D. Liu, H. P. Lehmann, K. D. Frick and H. B. Carter. J Urol 2012; 187: 1241-1246. J Urol. 2012 Oct; 188(4):1400; author reply 1400. PMID: 22906654.
      Citations:    Fields:    Translation:Humans
    212. Pinsky PF, Black A, Grubb R, Crawford ED, Andriole G, Thompson I, Parnes H. Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials. Cancer. 2013 Feb 01; 119(3):593-601. PMID: 22893105.
      Citations: 7     Fields:    Translation:Humans
    213. Kristal AR, Till C, Tangen CM, Goodman PJ, Neuhouser ML, Stanczyk FZ, Chu LW, Patel SK, Thompson IM, Reichardt JK, Hoque A, Platz EA, Figg WD, Van Bokhoven A, Lippman SM, Hsing AW. Associations of serum sex steroid hormone and 5a-androstane-3a,17ß-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride. Cancer Epidemiol Biomarkers Prev. 2012 Oct; 21(10):1823-32. PMID: 22879203.
      Citations: 6     Fields:    Translation:Humans
    214. Liang Y, Du F, Thompson IM, Turner BJ. Limited PSA testing in indigent men in South Texas: an appropriate care or missing a prevention opportunity? Cancer Epidemiol Biomarkers Prev. 2012 Sep; 21(9):1489-96. PMID: 22822113.
      Citations: 2     Fields:    Translation:Humans
    215. Thompson IM, Tangen CM. Prostate cancer--uncertainty and a way forward. N Engl J Med. 2012 Jul 19; 367(3):270-1. PMID: 22808963.
      Citations: 18     Fields:    Translation:Humans
    216. Sutcliffe S, Till C, Gaydos CA, Jenkins FJ, Goodman PJ, Hoque AM, Hsing AW, Thompson IM, Zenilman JM, Nelson WG, De Marzo AM, Platz EA. Prospective study of cytomegalovirus serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial. Cancer Causes Control. 2012 Sep; 23(9):1511-8. PMID: 22810146.
      Citations: 2     Fields:    Translation:HumansCells
    217. Basch E, Oliver TK, Vickers A, Thompson I, Kantoff P, Parnes H, Loblaw DA, Roth B, Williams J, Nam RK. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol. 2012 Aug 20; 30(24):3020-5. PMID: 22802323.
      Citations: 48     Fields:    Translation:Humans
    218. Schenk JM, Calip GS, Tangen CM, Goodman P, Parsons JK, Thompson IM, Kristal AR. Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2012 Jul 15; 176(2):156-63. PMID: 22759721.
      Citations: 8     Fields:    Translation:Humans
    219. Leach R, Thompson IM. The dilemma of prostate-specific antigen testing. Arch Intern Med. 2012 Jun 11; 172(11):835-6. PMID: 22905350.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    220. Li C, Zeliadt SB, Hall IJ, Smith JL, Ekwueme DU, Moinpour CM, Penson DF, Thompson IM, Keane TE, Ramsey SD. Willingness to pay for prostate cancer treatment among patients and their family members at 1 year after diagnosis. Value Health. 2012 Jul-Aug; 15(5):716-23. PMID: 22867781.
      Citations: 3     Fields:    Translation:Humans
    221. Liang Y, Ketchum NS, Louden C, Jimenez-Rios MA, Thompson IM, Camarena-Reynoso HR. The use of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator in a Mexican referral population: a validation study. Urol Int. 2012; 89(1):9-16. PMID: 22626812.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    222. Liang Y, Ankerst DP, Feng Z, Fu R, Stanford JL, Thompson IM. The risk of biopsy-detectable prostate cancer using the prostate cancer prevention Trial Risk Calculator in a community setting. Urol Oncol. 2013 Nov; 31(8):1464-9. PMID: 22552047.
      Citations: 2     Fields:    Translation:Humans
    223. Ankerst DP, Boeck A, Freedland SJ, Jones JS, Cronin AM, Roobol MJ, Hugosson J, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Moreira DM, Schröder FH, Lilja H, Vickers AJ, Thompson IM. Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol. 2014 Feb; 32(1):185-91. PMID: 22527674.
      Citations: 9     Fields:    Translation:Humans
    224. Lotan Y, Goodman PJ, Youssef RF, Svatek RS, Shariat SF, Tangen CM, Thompson IM, Klein EA. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. J Urol. 2012 Jun; 187(6):2005-10. PMID: 22498220.
      Citations: 15     Fields:    Translation:Humans
    225. Parsons JK, Schenk JM, Arnold KB, Messer K, Till C, Thompson IM, Kristal AR. Finasteride reduces the risk of incident clinical benign prostatic hyperplasia. Eur Urol. 2012 Aug; 62(2):234-41. PMID: 22459892.
      Citations: 21     Fields:    Translation:Humans
    226. Berglund RK, Tangen CM, Powell IJ, Lowe BA, Haas GP, Carroll PR, Canby-Hagino ED, deVere White R, Hemstreet GP, Crawford ED, Thompson IM, Klein EA. Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109. Urology. 2012 Mar; 79(3):633-7. PMID: 22386416.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    227. Liu T, Hossain M, Schepmoes AA, Fillmore TL, Sokoll LJ, Kronewitter SR, Izmirlian G, Shi T, Qian WJ, Leach RJ, Thompson IM, Chan DW, Smith RD, Kagan J, Srivastava S, Rodland KD, Camp DG. Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests. J Proteomics. 2012 Aug 03; 75(15):4747-57. PMID: 22846433.
      Citations: 15     Fields:    Translation:Humans
    228. Liang Y, Messer JC, Louden C, Jimenez-Rios MA, Thompson IM, Camarena-Reynoso HR. Prostate cancer risk prediction in a urology clinic in Mexico. Urol Oncol. 2013 Oct; 31(7):1085-92. PMID: 22306115.
      Citations: 3     Fields:    Translation:Humans
    229. Thompson IM, Ankerst DP. Editorial for special issue on epidemiology and prevention of prostate cancer. World J Urol. 2012 Apr; 30(2):129-30. PMID: 22270263.
      Citations: 1     Fields:    Translation:Humans
    230. Klein EA, Thompson IM. Chemoprevention of prostate cancer: an updated view. World J Urol. 2012 Apr; 30(2):189-94. PMID: 22238120.
      Citations: 10     Fields:    Translation:Humans
    231. Thompson IM. Overdiagnosis and overtreatment of prostate cancer. Am Soc Clin Oncol Educ Book. 2012; e35-9. PMID: 24451827.
      Citations: 2     Fields:    
    232. Ankerst DP, Boeck A, Freedland SJ, Thompson IM, Cronin AM, Roobol MJ, Hugosson J, Stephen Jones J, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Moreira DM, Schröder FH, Lilja H, Vickers AJ. Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol. 2012 Apr; 30(2):181-7. PMID: 22210512.
      Citations: 25     Fields:    Translation:Humans
    233. Ankerst DP, Koniarski T, Liang Y, Leach RJ, Feng Z, Sanda MG, Partin AW, Chan DW, Kagan J, Sokoll L, Wei JT, Thompson IM. Updating risk prediction tools: a case study in prostate cancer. Biom J. 2012 Jan; 54(1):127-42. PMID: 22095849.
      Citations: 16     Fields:    Translation:Humans
    234. Williams SB, Salami S, Regan MM, Ankerst DP, Wei JT, Rubin MA, Thompson IM, Sanda MG. Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial. Cancer. 2012 May 15; 118(10):2651-8. PMID: 22006057.
      Citations: 11     Fields:    Translation:Humans
    235. Klein EA, Thompson IM, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12; 306(14):1549-56. PMID: 21990298.
      Citations: 497     Fields:    Translation:Humans
    236. Marshall JR, Tangen CM, Sakr WA, Wood DP, Berry DL, Klein EA, Lippman SM, Parnes HL, Alberts DS, Jarrard DF, Lee WR, Gaziano JM, Crawford ED, Ely B, Ray M, Davis W, Minasian LM, Thompson IM. Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prev Res (Phila). 2011 Nov; 4(11):1761-9. PMID: 21896650.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    237. Wang Z, Jiang T, Sauro S, Wang Y, Thompson I, Watson TF, Sa Y, Xing W, Shen Y, Haapasalo M. Dentine remineralization induced by two bioactive glasses developed for air abrasion purposes. J Dent. 2011 Nov; 39(11):746-56. PMID: 21864641.
      Citations: 5     Fields:    Translation:Humans
    238. Klotz L, Thompson I. Early prostate cancer--treat or watch? N Engl J Med. 2011 08 11; 365(6):569. PMID: 21830972.
      Citations: 4     Fields:    Translation:Humans
    239. Tang L, Yao S, Till C, Goodman PJ, Tangen CM, Wu Y, Kristal AR, Platz EA, Neuhouser ML, Stanczyk FZ, Reichardt JK, Santella RM, Hsing A, Hoque A, Lippman SM, Thompson IM, Ambrosone CB. Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Carcinogenesis. 2011 Oct; 32(10):1500-6. PMID: 21771722.
      Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
    240. Li C, Zolotarevsky E, Thompson I, Anderson MA, Simeone DM, Casper JM, Mullenix MC, Lubman DM. A multiplexed bead assay for profiling glycosylation patterns on serum protein biomarkers of pancreatic cancer. Electrophoresis. 2011 Aug; 32(15):2028-35. PMID: 21732554.
      Citations: 11     Fields:    Translation:HumansCells
    241. Rim SH, Hall IJ, Fairweather ME, Fedorenko CR, Ekwueme DU, Smith JL, Thompson IM, Keane TE, Penson DF, Moinpour CM, Zeliadt SB, Ramsey SD. Considering racial and ethnic preferences in communication and interactions among the patient, family member, and physician following diagnosis of localized prostate cancer: study of a US population. Int J Gen Med. 2011; 4:481-6. PMID: 21760749.
      Citations: 6     
    242. Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, Reichardt JK, Tang L, Neuhouser ML, Santella RM, Figg WD, Price DK, Parnes HL, Lippman SM, Thompson IM, Ambrosone CB, Hoque A. Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study. Cancer Causes Control. 2011 Aug; 22(8):1121-31. PMID: 21667068.
      Citations: 20     Fields:    Translation:Humans
    243. Beuten J, Halder I, Fowler SP, Groing HH, Duggirala R, Arya R, Thompson IM, Leach RJ, Lehman DM. Wide disparity in genetic admixture among Mexican Americans from San Antonio, TX. Ann Hum Genet. 2011 Jul; 75(4):529-38. PMID: 21592109.
      Citations: 11     Fields:    Translation:Humans
    244. Ankerst DP, Pollock BH, Liang Y, Dizdarevic N, Kyrylenko S, Boeck A, Thompson IM, Leach R. Trends and co-trends of prostate-specific antigen and body mass index in a screened population. Urology. 2011 Jul; 78(1):10-6. PMID: 21550639.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    245. Schenk JM, Kristal AR, Arnold KB, Tangen CM, Neuhouser ML, Lin DW, White E, Thompson IM. Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. Am J Epidemiol. 2011 Jun 15; 173(12):1419-28. PMID: 21540324.
      Citations: 23     Fields:    Translation:Humans
    246. Brasky TM, Till C, White E, Neuhouser ML, Song X, Goodman P, Thompson IM, King IB, Albanes D, Kristal AR. Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol. 2011 Jun 15; 173(12):1429-39. PMID: 21518693.
      Citations: 51     Fields:    Translation:Humans
    247. Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP, Wood DP, Sakr WA, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, Glode LM. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol. 2011 May 20; 29(15):2040-5. PMID: 21502546.
      Citations: 34     Fields:    Translation:Humans
    248. Hardman RL, El-Merhi F, Jung AJ, Ware S, Thompson IM, Friel HT, Peng Q. Fast T2*-weighted MRI of the prostate at 3 Tesla. J Magn Reson Imaging. 2011 Apr; 33(4):902-7. PMID: 21448956.
      Citations: 3     Fields:    Translation:Humans
    249. Sauro S, Thompson I, Watson TF. Effects of common dental materials used in preventive or operative dentistry on dentin permeability and remineralization. Oper Dent. 2011 Mar-Apr; 36(2):222-30. PMID: 21777102.
      Citations: 9     Fields:    Translation:HumansCells
    250. Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst. 2011 Mar 16; 103(6):462-9. PMID: 21350221.
      Citations: 42     Fields:    Translation:Humans
    251. Smith DC, Tangen CM, Van Veldhuizen PJ, Harrer GW, Golshayan A, Mills GM, Vogelzang NJ, Thompson IM, Hussain MH. Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032. Urology. 2011 May; 77(5):1172-6. PMID: 21334731.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    252. Kristal AR, Till C, Platz EA, Song X, King IB, Neuhouser ML, Ambrosone CB, Thompson IM. Serum lycopene concentration and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2011 Apr; 20(4):638-46. PMID: 21335507.
      Citations: 27     Fields:    Translation:Humans
    253. Zeliadt SB, Penson DF, Moinpour CM, Blough DK, Fedorenko CR, Hall IJ, Smith JL, Ekwueme DU, Thompson IM, Keane TE, Ramsey SD. Provider and partner interactions in the treatment decision-making process for newly diagnosed localized prostate cancer. BJU Int. 2011 Sep; 108(6):851-6; discussion 856-7. PMID: 21244609.
      Citations: 16     Fields:    Translation:Humans
    254. Thompson IM, Klotz L. Active surveillance for prostate cancer. JAMA. 2010 Dec 01; 304(21):2411-2. PMID: 21119090.
      Citations: 6     Fields:    Translation:Humans
    255. Goodman PJ, Tangen CM, Kristal AR, Thompson IM, Lucia MS, Platz EA, Figg WD, Hoque A, Hsing A, Neuhouser ML, Parnes HL, Reichardt JK, Santella RM, Till C, Lippman SM. Transition of a clinical trial into translational research: the prostate cancer prevention trial experience. Cancer Prev Res (Phila). 2010 Dec; 3(12):1523-33. PMID: 21149329.
      Citations: 18     Fields:    Translation:Humans
    256. Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman HB, Wood DP, de Vere White RW, Vogelzang NJ, Trump DL, Natale RB, Tangen CM, Crawford ED, Thompson IM. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int. 2011 Sep; 108(5):693-9. PMID: 21105991.
      Citations: 26     Fields:    Translation:Humans
    257. Liang Y, Ankerst DP, Ketchum NS, Ercole B, Shah G, Shaughnessy JD, Leach RJ, Thompson IM. Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. J Urol. 2011 Jan; 185(1):104-10. PMID: 21074193.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    258. Chang BL, Spangler E, Gallagher S, Haiman CA, Henderson B, Isaacs W, Benford ML, Kidd LR, Cooney K, Strom S, Ingles SA, Stern MC, Corral R, Joshi AD, Xu J, Giri VN, Rybicki B, Neslund-Dudas C, Kibel AS, Thompson IM, Leach RJ, Ostrander EA, Stanford JL, Witte J, Casey G, Eeles R, Hsing AW, Chanock S, Hu JJ, John EM, Park J, Stefflova K, Zeigler-Johnson C, Rebbeck TR. Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol Biomarkers Prev. 2011 Jan; 20(1):23-32. PMID: 21071540.
      Citations: 55     Fields:    Translation:Humans
    259. Ramsey SD, Zeliadt SB, Fedorenko CR, Blough DK, Moinpour CM, Hall IJ, Smith JL, Ekwueme DU, Fairweather ME, Thompson IM, Keane TE, Penson DF. Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions. World J Urol. 2011 Feb; 29(1):3-9. PMID: 20959991.
      Citations: 24     Fields:    Translation:Humans
    260. Price DK, Chau CH, Till C, Goodman PJ, Baum CE, Ockers SB, English BC, Minasian L, Parnes HL, Hsing AW, Reichardt JK, Hoque A, Tangen CM, Kristal AR, Thompson IM, Figg WD. Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial. J Urol. 2010 Dec; 184(6):2297-302. PMID: 20952028.
      Citations: 22     Fields:    Translation:HumansCells
    261. Liang Y, Ankerst DP, Sanchez M, Leach RJ, Thompson IM. Body mass index adjusted prostate-specific antigen and its application for prostate cancer screening. Urology. 2010 Nov; 76(5):1268.e1-6. PMID: 20739049.
      Citations: 12     Fields:    Translation:Humans
    262. Thompson IM, Ankerst DP, Tangen CM. Prostate-specific antigen, risk factors, and prostate cancer: confounders nestled in an enigma. J Natl Cancer Inst. 2010 Sep 08; 102(17):1299-301. PMID: 20724727.
      Citations: 3     Fields:    Translation:Humans
    263. Kristal AR, Arnold KB, Neuhouser ML, Goodman P, Platz EA, Albanes D, Thompson IM. Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol. 2010 Sep 01; 172(5):566-77. PMID: 20693267.
      Citations: 58     Fields:    Translation:Humans
    264. Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN, Van Veldhuizen PJ, Quinn DI, Vogelzang NJ, Thompson IM, Hussain MH. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res. 2010 Jun 01; 16(11):3028-34. PMID: 20484019.
      Citations: 77     Fields:    Translation:HumansCTClinical Trials
    265. Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL, Partin AW, Srivastava S, Thompson IM, Wei JT, Zhang Z, Chan DW. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev. 2010 May; 19(5):1193-200. PMID: 20447916.
      Citations: 78     Fields:    Translation:Humans
    266. Zeliadt SB, Moinpour CM, Blough DK, Penson DF, Hall IJ, Smith JL, Ekwueme DU, Thompson IM, Keane TE, Ramsey SD. Preliminary treatment considerations among men with newly diagnosed prostate cancer. Am J Manag Care. 2010 May 01; 16(5):e121-30. PMID: 20455638.
      Citations: 25     Fields:    Translation:Humans
    267. Kristal AR, Price DK, Till C, Schenk JM, Neuhouser ML, Ockers S, Lin DW, Thompson IM, Figg WD. Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Prostate. 2010 May 01; 70(6):584-90. PMID: 19938041.
      Citations: 4     Fields:    Translation:HumansCells
    268. Kumar AP, Graham H, Robson C, Thompson IM, Ghosh R. Natural products: potential for developing Phellodendron amurense bark extract for prostate cancer management. Mini Rev Med Chem. 2010 May; 10(5):388-97. PMID: 20370708.
      Citations: 4     Fields:    Translation:HumansAnimals
    269. Esserman L, Thompson I. Solving the overdiagnosis dilemma. J Natl Cancer Inst. 2010 May 05; 102(9):582-3. PMID: 20413743.
      Citations: 16     Fields:    Translation:HumansPHPublic Health
    270. Hoque A, Ambrosone CB, Till C, Goodman PJ, Tangen C, Kristal A, Lucia S, Wang Q, Kappil M, Thompson I, Hsing AW, Parnes H, Santella RM. Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila). 2010 Apr; 3(4):478-83. PMID: 20332306.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    271. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C, Smith RA. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010 Mar-Apr; 60(2):70-98. PMID: 20200110.
      Citations: 281     Fields:    Translation:HumansPHPublic Health
    272. Thompson IM. Editorial comment. Urology. 2010 Mar; 75(3):509-10. PMID: 20211359.
      Citations:    Fields:    Translation:Humans
    273. Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, Kratz M, Thompson IM. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2010 Mar 01; 171(5):571-82. PMID: 20142396.
      Citations: 42     Fields:    Translation:Humans
    274. Sauro S, Watson TF, Thompson I. Dentine desensitization induced by prophylactic and air-polishing procedures: an in vitro dentine permeability and confocal microscopy study. J Dent. 2010 May; 38(5):411-22. PMID: 20132859.
      Citations: 10     Fields:    Translation:Humans
    275. Sutcliffe S, Viscidi RP, Till C, Goodman PJ, Hoque AM, Hsing AW, Thompson IM, Zenilman JM, De Marzo AM, Platz EA. Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2010 Feb; 19(2):614-8. PMID: 20142255.
      Citations: 16     Fields:    Translation:HumansCells
    276. Beuten J, Gelfond JA, Franke JL, Shook S, Johnson-Pais TL, Thompson IM, Leach RJ. Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men. Cancer Epidemiol Biomarkers Prev. 2010 Feb; 19(2):588-99. PMID: 20086112.
      Citations: 21     Fields:    Translation:Humans
    277. Teichman JM, Sea J, Thompson IM, Elston DM. Noninfectious penile lesions. Am Fam Physician. 2010 Jan 15; 81(2):167-74. PMID: 20082512.
      Citations: 2     Fields:    Translation:Humans
    278. Eyre SJ, Ankerst DP, Wei JT, Nair PV, Regan MM, Bueti G, Tang J, Rubin MA, Kearney M, Thompson IM, Sanda MG. Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection. J Urol. 2009 Dec; 182(6):2653-8. PMID: 19836788.
      Citations: 24     Fields:    Translation:Humans
    279. Platz EA, Till C, Goodman PJ, Parnes HL, Figg WD, Albanes D, Neuhouser ML, Klein EA, Thompson IM, Kristal AR. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2009 Nov; 18(11):2807-13. PMID: 19887582.
      Citations: 69     Fields:    Translation:Humans
    280. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA. 2009 Oct 21; 302(15):1685-92. PMID: 19843904.
      Citations: 167     Fields:    Translation:HumansPHPublic Health
    281. Tangen CM, Goldman BH, Swanson GP, Thompson IM. Biased hormonal therapy duration analysis makes results uninterpretable. J Clin Oncol. 2009 Nov 20; 27(33):e203; author reply e204. PMID: 19786655.
      Citations: 1     Fields:    Translation:Humans
    282. Newcomb LF, Brooks JD, Carroll PR, Feng Z, Gleave ME, Nelson PS, Thompson IM, Lin DW. Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology. 2010 Feb; 75(2):407-13. PMID: 19758683.
      Citations: 28     Fields:    Translation:HumansPHPublic Health
    283. Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, Thompson IM. Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Prostate. 2009 Sep 01; 69(12):1303-11. PMID: 19475640.
      Citations: 8     Fields:    Translation:Humans
    284. Sarvis JA, Thompson IM. United States military contributions to the National Cancer Institute. Urol Oncol. 2009 Sep-Oct; 27(5):558-61. PMID: 19720303.
      Citations:    Fields:    Translation:Humans
    285. Beuten J, Garcia D, Brand TC, He X, Balic I, Canby-Hagino E, Troyer DA, Baillargeon J, Hernandez J, Thompson IM, Leach RJ, Naylor SL. Semaphorin 3B and 3F single nucleotide polymorphisms are associated with prostate cancer risk and poor prognosis. J Urol. 2009 Oct; 182(4):1614-20. PMID: 19683737.
      Citations: 8     Fields:    Translation:Humans
    286. Gong Z, Kristal AR, Schenk JM, Tangen CM, Goodman PJ, Thompson IM. Alcohol consumption, finasteride, and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer. 2009 Aug 15; 115(16):3661-9. PMID: 19598210.
      Citations: 23     Fields:    Translation:Humans
    287. Sauro S, Mannocci F, Toledano M, Osorio R, Thompson I, Watson TF. Influence of the hydrostatic pulpal pressure on droplets formation in current etch-and-rinse and self-etch adhesives: a video rate/TSM microscopy and fluid filtration study. Dent Mater. 2009 Nov; 25(11):1392-402. PMID: 19632714.
      Citations: 7     Fields:    Translation:HumansCells
    288. Brawley OW, Ankerst DP, Thompson IM. Screening for prostate cancer. CA Cancer J Clin. 2009 Jul-Aug; 59(4):264-73. PMID: 19564245.
      Citations: 26     Fields:    Translation:HumansPHPublic Health
    289. Beuten J, Gelfond JA, Martinez-Fierro ML, Weldon KS, Crandall AC, Rojas-Martinez A, Thompson IM, Leach RJ. Association of chromosome 8q variants with prostate cancer risk in Caucasian and Hispanic men. Carcinogenesis. 2009 Aug; 30(8):1372-9. PMID: 19528667.
      Citations: 20     Fields:    Translation:HumansCells
    290. Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Klein EA. Chemoprevention of prostate cancer. J Urol. 2009 Aug; 182(2):499-507; discussion 508. PMID: 19524966.
      Citations: 17     Fields:    Translation:Humans
    291. Beuten J, Gelfond JA, Franke JL, Weldon KS, Crandall AC, Johnson-Pais TL, Thompson IM, Leach RJ. Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2009 Jun; 18(6):1869-80. PMID: 19505920.
      Citations: 57     Fields:    Translation:Humans
    292. Thompson IM, Tangen CM, Klein EA. Is there a standard of care for pathologic stage T3 prostate cancer? J Clin Oncol. 2009 Jun 20; 27(18):2898-9. PMID: 19433682.
      Citations: 12     Fields:    Translation:Humans
    293. Ankerst DP, Miyamoto R, Nair PV, Pollock BH, Thompson IM, Parekh DJ. Yearly prostate specific antigen and digital rectal examination fluctuations in a screened population. J Urol. 2009 May; 181(5):2071-5; discussion 2076. PMID: 19286205.
      Citations: 7     Fields:    Translation:HumansPHPublic Health
    294. Wang C, Nieschlag E, Swerdloff RS, Behre H, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male. 2009 Mar; 12(1):5-12. PMID: 18763169.
      Citations: 25     Fields:    Translation:Humans
    295. Rittmaster RS, Fleshner NE, Thompson IM. Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol. 2009 May; 55(5):1064-73. PMID: 19200641.
      Citations: 6     Fields:    Translation:HumansPHPublic Health
    296. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009 Mar; 181(3):956-62. PMID: 19167731.
      Citations: 298     Fields:    Translation:Humans
    297. Dorff TB, Tangen CM, Crawford ED, Petrylak DP, Higano CS, Raghavan D, Quinn DI, Vogelzang NJ, Thompson IM, Hussain MH. COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER. Ther Adv Med Oncol. 2009; 1(2):69-77. PMID: 21085622.
      Citations:    
    298. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL, Baker LH, Coltman CA. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 07; 301(1):39-51. PMID: 19066370.
      Citations: 659     Fields:    Translation:HumansCTClinical Trials
    299. Thompson IM. Editorial Comment on adjuvant radiotherapy study. Urology. 2008 Dec 01; 72(6):1303-1304. PMID: 20657714.
      Citations:    Fields:    
    300. Kim K, Aronov P, Zakharkin SO, Anderson D, Perroud B, Thompson IM, Weiss RH. Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics. 2009 Mar; 8(3):558-70. PMID: 19008263.
      Citations: 81     Fields:    Translation:Humans
    301. Sarvis JA, Thompson IM. Prostate cancer chemoprevention: update of the prostate cancer prevention trial findings and implications for clinical practice. Curr Oncol Rep. 2008 Nov; 10(6):529-32. PMID: 18928669.
      Citations: 6     Fields:    Translation:Humans
    302. Thompson IM, Tangen CM, Kristal AR. Prostate-specific antigen: a misused and maligned prostate cancer biomarker. J Natl Cancer Inst. 2008 Nov 05; 100(21):1487-8. PMID: 18957671.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    303. Kristal AR, Schenk JM, Song Y, Arnold KB, Neuhouser ML, Goodman PJ, Lin DW, Stanczyk FZ, Thompson IM. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2008 Dec 15; 168(12):1416-24. PMID: 18945688.
      Citations: 37     Fields:    Translation:Humans
    304. Swanson GP, Goldman B, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD, Thompson IM, Crawford ED. The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794. J Urol. 2008 Dec; 180(6):2453-7; discussion 2458. PMID: 18930488.
      Citations: 14     Fields:    Translation:Humans
    305. Neuhouser ML, Schenk J, Song YJ, Tangen CM, Goodman PJ, Pollak M, Penson DF, Thompson IM, Kristal AR. Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. Prostate. 2008 Sep 15; 68(13):1477-86. PMID: 18618736.
      Citations: 26     Fields:    Translation:Humans
    306. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol. 2009 Jan; 55(1):121-30. PMID: 18762364.
      Citations: 56     Fields:    Translation:Humans
    307. Thompson IM, Ankerst DP, Etzioni R, Wang T. It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer. J Urol. 2008 Oct; 180(4):1219-22. PMID: 18707707.
      Citations: 6     Fields:    Translation:Humans
    308. Ankerst DP, Groskopf J, Day JR, Blase A, Rittenhouse H, Pollock BH, Tangen C, Parekh D, Leach RJ, Thompson I. Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J Urol. 2008 Oct; 180(4):1303-8; discussion 1308. PMID: 18707724.
      Citations: 28     Fields:    Translation:HumansPHPublic Health
    309. Thompson IM, Tangen CM, Ankerst DP, Chi C, Lucia MS, Goodman P, Parnes H, Coltman CA. The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy. J Urol. 2008 Aug; 180(2):544-7. PMID: 18550097.
      Citations: 5     Fields:    Translation:HumansPHPublic Health
    310. Sokoll LJ, Wang Y, Feng Z, Kagan J, Partin AW, Sanda MG, Thompson IM, Chan DW. [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol. 2008 Aug; 180(2):539-43; discussion 543. PMID: 18550118.
      Citations: 30     Fields:    Translation:Humans
    311. Reed AB, Ankerst DP, Leach RJ, Vipraio G, Thompson IM, Parekh DJ. Total prostate specific antigen stability confirmed after long-term storage of serum at -80C. J Urol. 2008 Aug; 180(2):534-7; discussion 537-8. PMID: 18550121.
      Citations: 2     Fields:    Translation:Humans
    312. Beuten J, Gelfond JA, Byrne JJ, Balic I, Crandall AC, Johnson-Pais TL, Thompson IM, Price DK, Leach RJ. CYP1B1 variants are associated with prostate cancer in non-Hispanic and Hispanic Caucasians. Carcinogenesis. 2008 Sep; 29(9):1751-7. PMID: 18544568.
      Citations: 20     Fields:    Translation:Humans
    313. Sarvis JA, Thompson IM. Androgens and prevention of prostate cancer. Curr Opin Endocrinol Diabetes Obes. 2008 Jun; 15(3):271-7. PMID: 18438176.
      Citations:    Fields:    Translation:HumansCells
    314. Lucia MS, Darke AK, Goodman PJ, La Rosa FG, Parnes HL, Ford LG, Coltman CA, Thompson IM. Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res (Phila). 2008 Aug; 1(3):167-73. PMID: 19138952.
      Citations: 25     Fields:    Translation:Humans
    315. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA, Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila). 2008 Aug; 1(3):174-81. PMID: 19138953.
      Citations: 61     Fields:    Translation:Humans
    316. Torkko KC, van Bokhoven A, Mai P, Beuten J, Balic I, Byers TE, Hokanson JE, Norris JM, Barón AE, Lucia MS, Thompson IM, Leach RJ. VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men. Clin Cancer Res. 2008 May 15; 14(10):3223-9. PMID: 18483391.
      Citations: 21     Fields:    Translation:Humans
    317. Thompson IM, Tangen CM, Parnes HL, Lippman SM, Coltman CA. Does the level of prostate cancer risk affect cancer prevention with finasteride? Urology. 2008 May; 71(5):854-7. PMID: 18455628.
      Citations: 7     Fields:    Translation:Humans
    318. Thompson IM, Tangen CM, Lucia MS. The Prostate Cancer Prevention Trial and the future of chemoprevention. BJU Int. 2008 Apr; 101(8):933-4. PMID: 18353157.
      Citations: 1     Fields:    Translation:Humans
    319. Song Y, Tangen C, Goodman P, Parnes HL, Lucia MS, Thompson IM, Kristal AR. Finasteride, prostate cancer, and weight gain: evidence for genetic or environmental factors that affect cancer outcomes during finasteride treatment. Prostate. 2008 Feb 15; 68(3):281-6. PMID: 18163420.
      Citations: 5     Fields:    Translation:Humans
    320. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman P, Penson DF, Thompson IM. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2008 Apr 15; 167(8):925-34. PMID: 18263602.
      Citations: 62     Fields:    Translation:Humans
    321. Heath EI, Kattan MW, Powell IJ, Sakr W, Brand TC, Rybicki BA, Thompson IM, Aronson WJ, Terris MK, Kane CJ, Presti JC, Amling CL, Freedland SJ. The effect of race/ethnicity on the accuracy of the 2001 Partin Tables for predicting pathologic stage of localized prostate cancer. Urology. 2008 Jan; 71(1):151-5. PMID: 18242385.
      Citations: 6     Fields:    Translation:Humans
    322. Moinpour CM, Hayden KA, Unger JM, Thompson IM, Redman MW, Canby-Hagino ED, Higgins BA, Sullivan JW, Lemmon D, Breslin S, Crawford ED. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol. 2008 Jan 01; 26(1):112-20. PMID: 18165645.
      Citations: 31     Fields:    Translation:Humans
    323. Brand TC, Bermejo C, Canby-Hagino E, Troyer DA, Baillargeon J, Thompson IM, Leach RJ, Naylor SL. Association of polymorphisms in TGFB1 and prostate cancer prognosis. J Urol. 2008 Feb; 179(2):754-8. PMID: 18082198.
      Citations: 6     Fields:    Translation:Humans
    324. McLerran D, Grizzle WE, Feng Z, Thompson IM, Bigbee WL, Cazares LH, Chan DW, Dahlgren J, Diaz J, Kagan J, Lin DW, Malik G, Oelschlager D, Partin A, Randolph TW, Sokoll L, Srivastava S, Srivastava S, Thornquist M, Troyer D, Wright GL, Zhang Z, Zhu L, Semmes OJ. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem. 2008 Jan; 54(1):53-60. PMID: 18024530.
      Citations: 37     Fields:    Translation:Humans
    325. Pepe MS, Feng Z, Huang Y, Longton G, Prentice R, Thompson IM, Zheng Y. Integrating the predictiveness of a marker with its performance as a classifier. Am J Epidemiol. 2008 Feb 01; 167(3):362-8. PMID: 17982157.
      Citations: 118     Fields:    Translation:Humans
    326. McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH, Chan DW, Diaz J, Izbicka E, Kagan J, Malehorn DE, Malik G, Oelschlager D, Partin A, Randolph T, Rosenzweig N, Srivastava S, Srivastava S, Thompson IM, Thornquist M, Troyer D, Yasui Y, Zhang Z, Zhu L, Semmes OJ. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem. 2008 Jan; 54(1):44-52. PMID: 17981926.
      Citations: 37     Fields:    Translation:Humans
    327. Ghosh R, Garcia GE, Crosby K, Inoue H, Thompson IM, Troyer DA, Kumar AP. Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine. Neoplasia. 2007 Nov; 9(11):893-9. PMID: 18030357.
      Citations: 22     Fields:    Translation:HumansCells
    328. Swanson GP, Thompson IM. Adjuvant radiotherapy for high-risk patients following radical prostatectomy. Urol Oncol. 2007 Nov-Dec; 25(6):515-9. PMID: 18047963.
      Citations: 1     Fields:    Translation:Humans
    329. Parekh DJ, Ankerst DP, Troyer D, Srivastava S, Thompson IM. Biomarkers for prostate cancer detection. J Urol. 2007 Dec; 178(6):2252-9. PMID: 17936845.
      Citations: 28     Fields:    Translation:HumansPHPublic Health
    330. Etzioni RD, Ankerst DP, Weiss NS, Inoue LY, Thompson IM. Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. J Natl Cancer Inst. 2007 Oct 17; 99(20):1510-5. PMID: 17925534.
      Citations: 15     Fields:    Translation:HumansPHPublic Health
    331. Parekh DJ, Ankerst DP, Baillargeon J, Higgins B, Platz EA, Troyer D, Hernandez J, Leach RJ, Lokshin A, Thompson IM. Assessment of 54 biomarkers for biopsy-detectable prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007 Oct; 16(10):1966-72. PMID: 17932343.
      Citations: 7     Fields:    Translation:Humans
    332. Canby-Hagino E, Hernandez J, Brand TC, Troyer DA, Higgins B, Ankerst DP, Thompson IM, Leach RJ, Parekh DJ. Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL. Urology. 2007 Oct; 70(4):748-52. PMID: 17991549.
      Citations: 3     Fields:    Translation:Humans
    333. Shook SJ, Beuten J, Torkko KC, Johnson-Pais TL, Troyer DA, Thompson IM, Leach RJ. Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans. Clin Cancer Res. 2007 Oct 01; 13(19):5959-64. PMID: 17908993.
      Citations: 23     Fields:    Translation:Humans
    334. Reed A, Ankerst DP, Pollock BH, Thompson IM, Parekh DJ. Current age and race adjusted prostate specific antigen threshold values delay diagnosis of high grade prostate cancer. J Urol. 2007 Nov; 178(5):1929-32; discussion 1932. PMID: 17868724.
      Citations: 8     Fields:    Translation:Humans
    335. Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, Tangen CM, Parnes HL, Lippman SM, La Rosa FG, Kattan MW, Crawford ED, Ford LG, Coltman CA, Thompson IM. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007 Sep 19; 99(18):1375-83. PMID: 17848673.
      Citations: 66     Fields:    Translation:Humans
    336. Thompson IM, Pauler Ankerst D, Chi C, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol. 2007 Jul 20; 25(21):3076-81. PMID: 17634486.
      Citations: 24     Fields:    Translation:Humans
    337. Thompson IM. Chemoprevention of prostate cancer: agents and study designs. J Urol. 2007 Sep; 178(3 Pt 2):S9-S13. PMID: 17644117.
      Citations: 10     Fields:    Translation:Humans
    338. Kantoff PW, Beer TM, D'Amico AV, Dipaola RS, Eisenberger MA, Hussain MH, Kelly WK, Mathew P, Morris MJ, Ryan CJ, Sandler HM, Thompson IM, Carroll PR. Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference. J Urol. 2007 Sep; 178(3 Pt 2):S5-8; quiz S4. PMID: 17644118.
      Citations:    Fields:    Translation:Humans
    339. Swanson GP, Carpenter WR, Thompson IM, Crawford ED. Urologists' attitudes regarding cancer clinical research. Urology. 2007 Jul; 70(1):19-24. PMID: 17656200.
      Citations: 4     Fields:    Translation:Humans
    340. Crawford ED, Thompson IM. Controversies regarding screening for prostate cancer. BJU Int. 2007 Jul; 100 Suppl 2:5-7. PMID: 17594348.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    341. Thompson IM. Chemoprevention of prostate cancer: lessons learned. BJU Int. 2007 Jul; 100 Suppl 2:15-7. PMID: 17594351.
      Citations: 1     Fields:    Translation:Humans
    342. Moinpour CM, Darke AK, Donaldson GW, Thompson IM, Langley C, Ankerst DP, Patrick DL, Ware JE, Ganz PA, Shumaker SA, Lippman SM, Coltman CA. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007 Jul 04; 99(13):1025-35. PMID: 17596576.
      Citations: 21     Fields:    Translation:Humans
    343. Thompson IM, Ankerst DP. Prostate-specific antigen in the early detection of prostate cancer. CMAJ. 2007 Jun 19; 176(13):1853-8. PMID: 17576986.
      Citations: 22     Fields:    Translation:Humans
    344. Burnett AL, Aus G, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus S, Liebert M, Moul JW, Tangen C, Thrasher JB, Thompson I. Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol. 2007 Aug; 178(2):597-601. PMID: 17570435.
      Citations: 51     Fields:    Translation:Humans
    345. Swanson GP, Hussey MA, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD, Thompson IM, Crawford ED. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol. 2007 Jun 01; 25(16):2225-9. PMID: 17538167.
      Citations: 72     Fields:    Translation:Humans
    346. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen CM. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007 Jun; 177(6):2106-31. PMID: 17509297.
      Citations: 348     Fields:    Translation:Humans
    347. Thompson IM, Lucia MS, Redman MW, Darke A, La Rosa FG, Parnes HL, Lippman SM, Coltman CA. Finasteride decreases the risk of prostatic intraepithelial neoplasia. J Urol. 2007 Jul; 178(1):107-9; discussion 110. PMID: 17499284.
      Citations: 12     Fields:    Translation:Humans
    348. Brand TC, Canby-Hagino E, Thompson IM. Testosterone replacement therapy and prostate cancer: a word of caution. Curr Urol Rep. 2007 May; 8(3):185-9. PMID: 17459266.
      Citations: 6     Fields:    Translation:Humans
    349. Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Parnes HL, Lippman SM, Coltman CA. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol. 2007 May; 177(5):1749-52. PMID: 17437804.
      Citations: 19     Fields:    Translation:Humans
    350. Thompson IM, Lucia MS, Tangen CM. Commentary: the ubiquity of prostate cancer: echoes of the past, implications for the present: "what has been will be again, what has been done will be done again; there is nothing new under the sun." ECCLESIASTES 1:9. Int J Epidemiol. 2007 Apr; 36(2):287-9. PMID: 17452387.
      Citations: 4     Fields:    Translation:Humans
    351. Parekh DJ, Ankerst DP, Thompson IM. Prostate-specific antigen levels, prostate-specific antigen kinetics, and prostate cancer prognosis: a tocsin calling for prospective studies. J Natl Cancer Inst. 2007 Apr 04; 99(7):496-7. PMID: 17405989.
      Citations: 1     Fields:    Translation:Humans
    352. Walsh RM, Thompson IM. Prostate cancer screening and disease management: how screening may have an unintended effect on survival and mortality-the camel's nose effect. J Urol. 2007 Apr; 177(4):1303-6. PMID: 17382719.
      Citations: 3     Fields:    Translation:HumansPHPublic Health
    353. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Weiss N, Goodman P, Antvelink CM, Penson DF, Thompson IM. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol. 2007 Apr; 177(4):1395-400; quiz 1591. PMID: 17382740.
      Citations: 80     Fields:    Translation:Humans
    354. Markland AD, Thompson IM, Ankerst DP, Higgins B, Kraus SR. Lack of disparity in lower urinary tract symptom severity between community-dwelling non-Hispanic white, Mexican-American, and African-American men. Urology. 2007 Apr; 69(4):697-702. PMID: 17445654.
      Citations: 2     Fields:    Translation:Humans
    355. Etzioni RD, Ankerst DP, Thompson IM. Re: Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst. 2007 Mar 21; 99(6):489-90; author reply 490. PMID: 17374841.
      Citations:    Fields:    Translation:Humans
    356. Ankerst DP, Thompson IM. Understanding mixed messages about prostate specific antigen: biases in the evaluation of cancer biomarkers. J Urol. 2007 Feb; 177(2):426-7. PMID: 17222602.
      Citations:    Fields:    Translation:Humans
    357. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen C, Thrasher JB, Thompson I. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007 Feb; 177(2):540-5. PMID: 17222629.
      Citations: 217     Fields:    Translation:Humans
    358. Roach M, Weinberg V, Sandler H, Thompson I. Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score? Cancer. 2007 Jan 15; 109(2):213-20. PMID: 17167758.
      Citations: 5     Fields:    Translation:Humans
    359. Parekh DJ, Ankerst DP, Higgins BA, Hernandez J, Canby-Hagino E, Brand T, Troyer DA, Leach RJ, Thompson IM. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology. 2006 Dec; 68(6):1152-5. PMID: 17169636.
      Citations: 37     Fields:    Translation:HumansPHPublic Health
    360. Ankerst DP, Thompson IM. Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification. Arch Ital Urol Androl. 2006 Dec; 78(4):125-9. PMID: 17269614.
      Citations: 21     Fields:    Translation:Humans
    361. Ankerst DP, Thompson IM. Merging digital rectal exam, family history, age and prostate-specific antigen to create a decision-making tool. Arch Ital Urol Androl. 2006 Dec; 78(4):143-6. PMID: 17269618.
      Citations:    Fields:    Translation:Humans
    362. Ankerst DP, Thompson IM. New answers from the Prostate Cancer Prevention Trial on the chemoprevention of prostate cancer. Arch Ital Urol Androl. 2006 Dec; 78(4):154-6. PMID: 17269622.
      Citations: 2     Fields:    Translation:Humans
    363. Thompson IM. Defining high risk prostate cancer--where do we set the bar? A translational science approach to risk stratification. J Urol. 2006 Dec; 176(6 Pt 2):S21-4; discussion S25-6. PMID: 17084160.
      Citations: 3     Fields:    Translation:Humans
    364. Thompson IM, Carroll PR, Carducci MA. Recommendations for defining and treating high risk localized prostate cancer. J Urol. 2006 Dec; 176(6 Pt 2):S6-S10; quiz S3-5. PMID: 17084170.
      Citations: 7     Fields:    Translation:Humans
    365. Wilt TJ, Thompson IM. Clinically localised prostate cancer. BMJ. 2006 Nov 25; 333(7578):1102-6. PMID: 17124221.
      Citations: 5     Fields:    Translation:Humans
    366. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006 Nov 15; 296(19):2329-35. PMID: 17105795.
      Citations: 195     Fields:    Translation:Humans
    367. Swanson G, Thompson I, Basler J, Crawford ED. Metastatic prostate cancer-does treatment of the primary tumor matter? J Urol. 2006 Oct; 176(4 Pt 1):1292-8. PMID: 16952615.
      Citations: 15     Fields:    Translation:Humans
    368. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, Lippman SM, Platz EA, Pollak MN, Thompson IM, Kristal AR. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2006 Oct; 15(10):1977-83. PMID: 17035408.
      Citations: 120     Fields:    Translation:Humans
    369. Canby-Hagino E, Hernandez J, Brand TC, Thompson I. Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention. Eur Urol. 2007 Jan; 51(1):27-33. PMID: 17030406.
      Citations: 3     Fields:    Translation:Humans
    370. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006 Aug 16; 98(16):1128-33. PMID: 16912265.
      Citations: 82     Fields:    Translation:Humans
    371. Marshall JR, Sakr W, Wood D, Berry D, Tangen C, Parker F, Thompson I, Lippman SM, Lieberman R, Alberts D, Jarrard D, Coltman C, Greenwald P, Minasian L, Crawford ED. Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev. 2006 Aug; 15(8):1479-84. PMID: 16896036.
      Citations: 16     Fields:    Translation:Humans
    372. Brand TC, Canby-Hagino ED, Pratap Kumar A, Ghosh R, Leach RJ, Thompson IM. Chemoprevention of prostate cancer. Hematol Oncol Clin North Am. 2006 Aug; 20(4):831-43. PMID: 16861117.
      Citations: 4     Fields:    Translation:Humans
    373. Swanson GP, Thompson IM, Basler J. Current status of lymph node-positive prostate cancer: Incidence and predictors of outcome. Cancer. 2006 Aug 01; 107(3):439-50. PMID: 16795064.
      Citations: 17     Fields:    Translation:Humans
    374. Swanson GP, Faulkner J, Smalley SR, Noble MJ, Stephens RL, O'Rourke TJ, Weiss GR, Quick DP, Thompson IM, Crawford ED. Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024. J Urol. 2006 Aug; 176(2):548-53; discussion 553. PMID: 16813886.
      Citations: 3     Fields:    Translation:Humans
    375. Baillargeon J, Platz EA, Rose DP, Pollock BH, Ankerst DP, Haffner S, Higgins B, Lokshin A, Troyer D, Hernandez J, Lynch S, Leach RJ, Thompson IM. Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiol Biomarkers Prev. 2006 Jul; 15(7):1331-5. PMID: 16835332.
      Citations: 50     Fields:    Translation:Humans
    376. Swanson GP, Thompson IM, Basler J. Treatment options in lymph node-positive prostate cancer. Cancer. 2006 Jun 15; 106(12):2531-9. PMID: 16700035.
      Citations: 6     Fields:    Translation:Humans
    377. Goodman PJ, Thompson IM, Tangen CM, Crowley JJ, Ford LG, Coltman CA. The prostate cancer prevention trial: design, biases and interpretation of study results. J Urol. 2006 Jun; 175(6):2234-42. PMID: 16697846.
      Citations: 14     Fields:    Translation:Humans
    378. Thompson IM, Tangen CM. Does prostate volume affect accurate grading of prostate biopsies? Nat Clin Pract Urol. 2006 Jun; 3(6):298-9. PMID: 16763636.
      Citations: 1     Fields:    Translation:Humans
    379. Thompson IM, Lucia MS. Diagnosing prostate cancer: through a glass, darkly. J Urol. 2006 May; 175(5):1598-9. PMID: 16600709.
      Citations: 2     Fields:    Translation:Humans
    380. Brand TC, Hernandez J, Canby-Hagino ED, Basler JW, Thompson IM. Prostate cancer detection strategies. Curr Urol Rep. 2006 May; 7(3):181-5. PMID: 16630521.
      Citations: 1     Fields:    Translation:Humans
    381. Canby-Hagino ED, Brand TC, Hernandez J, Thompson IM. Chemoprevention of prostate cancer with finasteride. Expert Opin Pharmacother. 2006 May; 7(7):899-905. PMID: 16634712.
      Citations: 1     Fields:    Translation:HumansAnimals
    382. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006 Apr 19; 98(8):529-34. PMID: 16622122.
      Citations: 285     Fields:    Translation:Humans
    383. Vijayakumar S, Hall DC, Reveles XT, Troyer DA, Thompson IM, Garcia D, Xiang R, Leach RJ, Johnson-Pais TL, Naylor SL. Detection of recurrent copy number loss at Yp11.2 involving TSPY gene cluster in prostate cancer using array-based comparative genomic hybridization. Cancer Res. 2006 Apr 15; 66(8):4055-64. PMID: 16618725.
      Citations: 11     Fields:    Translation:HumansCells
    384. Sabichi AL, Lee JJ, Taylor RJ, Thompson IM, Miles BJ, Tangen CM, Minasian LM, Pisters LL, Caton JR, Basler JW, Lerner SP, Menter DG, Marshall JR, Crawford ED, Lippman SM. Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 1):2178-84. PMID: 16609032.
      Citations: 15     Fields:    Translation:Humans
    385. Hernández J, Balic I, Johnson-Pais TL, Higgins BA, Torkko KC, Thompson IM, Leach RJ. Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men. J Urol. 2006 Feb; 175(2):523-7. PMID: 16406987.
      Citations: 19     Fields:    Translation:Humans
    386. Kristal AR, Chi C, Tangen CM, Goodman PJ, Etzioni R, Thompson IM. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer. 2006 Jan 15; 106(2):320-8. PMID: 16342294.
      Citations: 28     Fields:    Translation:Humans
    387. Hudak SJ, Hernandez J, Thompson IM. Role of 5 alpha-reductase inhibitors in the management of prostate cancer. Clin Interv Aging. 2006; 1(4):425-31. PMID: 18046919.
      Citations: 2     Fields:    Translation:Humans
    388. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA. 2005 Dec 21; 294(23):2996-3002. PMID: 16414947.
      Citations: 171     Fields:    Translation:Humans
    389. Thompson IM, Tangen CM, Klein EA, Lippman SM. Phase III prostate cancer prevention trials: are the costs justified? J Clin Oncol. 2005 Nov 10; 23(32):8161-4. PMID: 16278467.
      Citations: 8     Fields:    Translation:HumansPHPublic Health
    390. Beddar AS. Stability of a mobile electron linear accelerator system for intraoperative radiation therapy. Med Phys. 2005 Oct; 32(10):3128-31. PMID: 29951640.
      Citations: 2     
    391. Thompson IM, Bermejo C, Hernandez J, Basler JA, Canby-Hagino E. Screening for prostate cancer: opportunities and challenges. Surg Oncol Clin N Am. 2005 Oct; 14(4):747-60. PMID: 16226689.
      Citations:    Fields:    Translation:Humans
    392. Klein EA, Tangen CM, Goodman PJ, Lippman SM, Thompson IM. Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited. J Clin Oncol. 2005 Oct 20; 23(30):7460-6. PMID: 16157937.
      Citations: 2     Fields:    Translation:Humans
    393. Thompson IM, Canby-Hagino E, Lucia MS. Stage migration and grade inflation in prostate cancer: Will Rogers meets Garrison Keillor. J Natl Cancer Inst. 2005 Sep 07; 97(17):1236-7. PMID: 16145036.
      Citations: 12     Fields:    Translation:Humans
    394. Etzioni RD, Howlader N, Shaw PA, Ankerst DP, Penson DF, Goodman PJ, Thompson IM. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol. 2005 Sep; 174(3):877-81. PMID: 16093979.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    395. Zeliadt SB, Etzioni RD, Penson DF, Thompson IM, Ramsey SD. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med. 2005 Aug; 118(8):850-7. PMID: 16084177.
      Citations: 12     Fields:    Translation:Humans
    396. Hernáandez J, Syed S, Weiss G, Fernandes G, von Merveldt D, Troyer DA, Basler JW, Thompson IM. The modulation of prostate cancer risk with alpha-tocopherol: a pilot randomized, controlled clinical trial. J Urol. 2005 Aug; 174(2):519-22. PMID: 16006884.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    397. Thompson KE, Hernández J, Canby-Hagino ED, Troyer D, Thompson IM. Prognostic features in men who died of prostate cancer. J Urol. 2005 Aug; 174(2):553-6; discussion 556. PMID: 16006890.
      Citations: 9     Fields:    Translation:Humans
    398. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, Parnes HL, Coltman CA. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA. 2005 Jul 06; 294(1):66-70. PMID: 15998892.
      Citations: 179     Fields:    Translation:Humans
    399. Tolcher AW, Chi K, Kuhn J, Gleave M, Patnaik A, Takimoto C, Schwartz G, Thompson I, Berg K, D'Aloisio S, Murray N, Frankel SR, Izbicka E, Rowinsky E. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2005 May 15; 11(10):3854-61. PMID: 15897586.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    400. Dipaola RS, Thompson IM. National cooperative group trials. Urology. 2005 May; 65(5 Suppl):23-9; discussion 29. PMID: 15885277.
      Citations: 2     Fields:    Translation:Humans
    401. Hernandez J, Canby-Hagino E, Thompson IM. Biomarkers for the detection and prognosis of prostate cancer. Curr Urol Rep. 2005 May; 6(3):171-6. PMID: 15869720.
      Citations: 2     Fields:    Translation:Humans
    402. Mahal K, Hernandez J, Basler JW, Thompson IM. What's new in the field of prostate cancer chemoprevention? Curr Urol Rep. 2005 May; 6(3):177-82. PMID: 15869721.
      Citations:    Fields:    Translation:Humans
    403. Canby-Hagino ED, Swanson GP, Crawford ED, Basler JW, Hernandez J, Thompson IM. Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated? Curr Urol Rep. 2005 May; 6(3):183-9. PMID: 15869722.
      Citations: 4     Fields:    Translation:Humans
    404. Canby-Hagino ED, Thompson IM. Mechanisms of disease: Prostate cancer--a model for cancer chemoprevention in clinical practice. Nat Clin Pract Oncol. 2005 May; 2(5):255-61. PMID: 16264961.
      Citations: 7     Fields:    Translation:Humans
    405. Williams MB, Hernandez J, Thompson I. Luteinizing hormone-releasing hormone agonist effects on skeletal muscle: how hormonal therapy in prostate cancer affects muscular strength. J Urol. 2005 Apr; 173(4):1067-71. PMID: 15758703.
      Citations: 7     Fields:    Translation:HumansCells
    406. Unger JM, Thompson IM, LeBlanc M, Crowley JJ, Goodman PJ, Ford LG, Coltman CA. Estimated impact of the Prostate Cancer Prevention Trial on population mortality. Cancer. 2005 Apr 01; 103(7):1375-80. PMID: 15739207.
      Citations: 5     Fields:    Translation:Humans
    407. Baillargeon J, Pollock BH, Kristal AR, Bradshaw P, Hernandez J, Basler J, Higgins B, Lynch S, Rozanski T, Troyer D, Thompson I. The association of body mass index and prostate-specific antigen in a population-based study. Cancer. 2005 Mar 01; 103(5):1092-5. PMID: 15668913.
      Citations: 55     Fields:    Translation:Humans
    408. Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM, Kristal AR, Santella RM, Probstfield JL, Moinpour CM, Albanes D, Taylor PR, Minasian LM, Hoque A, Thomas SM, Crowley JJ, Gaziano JM, Stanford JL, Cook ED, Fleshner NE, Lieber MM, Walther PJ, Khuri FR, Karp DD, Schwartz GG, Ford LG, Coltman CA. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst. 2005 Jan 19; 97(2):94-102. PMID: 15657339.
      Citations: 93     Fields:    Translation:Humans
    409. Parnes HL, Thompson IM, Ford LG. Prevention of hormone-related cancers: prostate cancer. J Clin Oncol. 2005 Jan 10; 23(2):368-77. PMID: 15637399.
      Citations: 12     Fields:    Translation:Humans
    410. Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Srivastava S, Thompson I, Welsh MJ, White N, Winget M, Yasui Y, Zhang Z, Zhu L. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem. 2005 Jan; 51(1):102-12. PMID: 15613711.
      Citations: 80     Fields:    Translation:Humans
    411. Beer TM, Tangen CM, Bland LB, Thompson IM, Crawford ED. Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of southwest oncology group study 8894. J Urol. 2004 Dec; 172(6 Pt 1):2213-7. PMID: 15538234.
      Citations: 8     Fields:    Translation:Humans
    412. Bermejo C, Kristal AR, Zeliadt SB, Ramsey S, Thompson IM. Localized prostate cancer: quality of life meets Whitmore's legacy. J Natl Cancer Inst. 2004 Sep 15; 96(18):1348-9. PMID: 15367562.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    413. Hernández J, Thompson IM. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer. 2004 Sep 01; 101(5):894-904. PMID: 15329895.
      Citations: 66     Fields:    Translation:HumansPHPublic Health
    414. Tolcher AW, Kuhn J, Schwartz G, Patnaik A, Hammond LA, Thompson I, Fingert H, Bushnell D, Malik S, Kreisberg J, Izbicka E, Smetzer L, Rowinsky EK. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2004 Aug 01; 10(15):5048-57. PMID: 15297406.
      Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
    415. Grizzle WE, Semmes OJ, Basler J, Izbicka E, Feng Z, Kagan J, Adam BL, Troyer D, Srivastava S, Thornquist M, Zhang Z, Thompson IM. The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology. Urol Oncol. 2004 Jul-Aug; 22(4):337-43. PMID: 15283893.
      Citations: 11     Fields:    Translation:HumansPHPublic Health
    416. Unger JM, LeBlanc M, Thompson IM, Coltman CA. The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies. Urol Oncol. 2004 Jul-Aug; 22(4):362-8. PMID: 15283898.
      Citations: 3     Fields:    Translation:Humans
    417. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004 May 27; 350(22):2239-46. PMID: 15163773.
      Citations: 561     Fields:    Translation:HumansCTClinical Trials
    418. Mahal K, Hernandez J, Basler JW, Thompson IM. What's new in the field of prostate cancer chemoprevention? Curr Oncol Rep. 2004 May; 6(3):237-42. PMID: 15066236.
      Citations:    Fields:    Translation:Humans
    419. Klein EA, Thompson IM. Update on chemoprevention of prostate cancer. Curr Opin Urol. 2004 May; 14(3):143-9. PMID: 15069304.
      Citations: 20     Fields:    Translation:Humans
    420. Hernandez J, Basler JW, Thompson IM. The potential role of cyclooxygenase-2 inhibitors and 5alpha-reductase inhibitors in the prevention of urologic conditions. Urol Clin North Am. 2004 May; 31(2):213-8. PMID: 15123401.
      Citations:    Fields:    Translation:Humans
    421. Goodman PJ, Tangen CM, Crowley JJ, Carlin SM, Ryan A, Coltman CA, Ford LG, Thompson IM. Implementation of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials. 2004 Apr; 25(2):203-22. PMID: 15020037.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    422. Hernandez J, Thompson IM. Diagnosis and treatment of prostate cancer. Med Clin North Am. 2004 Mar; 88(2):267-79, ix. PMID: 15049578.
      Citations:    Fields:    Translation:Humans
    423. Thompson IM, Leach R, Troyer D, Pollock B, Naylor S, Higgins B. Relationship of body mass index and prostate specific antigen in a population-based study. Urol Oncol. 2004 Mar-Apr; 22(2):127-31. PMID: 15082010.
      Citations: 6     Fields:    Translation:HumansPHPublic Health
    424. Thompson IM, Albanes D, Basler JW, Crawford ED, Denis LJ, Djavan B, Fleshner N, Johnson-Pais TL, Klein EA, Kristal AR, Lucia MS, Parnes HL, Piazza GA, Platz EA, Pollock BH, Price DK, Reichardt JK, Tangen CM, Tolcher AW, McMann MC. First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statement. J Urol. 2004 Feb; 171(2 Pt 2):S3-4. PMID: 14713744.
      Citations:    Fields:    Translation:Humans
    425. Barqawi A, Thompson IM, Crawford ED. Prostate cancer chemoprevention: an overview of United States trials. J Urol. 2004 Feb; 171(2 Pt 2):S5-8; discussion S9. PMID: 14713745.
      Citations: 3     Fields:    Translation:HumansAnimals
    426. Higgins B, Thompson IM. The Prostate Cancer Prevention Trial: current status. J Urol. 2004 Feb; 171(2 Pt 2):S15-7; discussion S8. PMID: 14713747.
      Citations: 2     Fields:    Translation:Humans
    427. Tangen CM, Goodman PJ, Crowley JJ, Thompson IM. Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. J Urol. 2004 Feb; 171(2 Pt 2):S64-7. PMID: 14713757.
      Citations: 2     Fields:    Translation:Humans
    428. Thompson IM, Klein EA, Lippman SM, Coltman CA, Djavan B. Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol. 2003 Dec; 44(6):650-5. PMID: 14644115.
      Citations: 14     Fields:    Translation:HumansPHPublic Health
    429. Unger JM, LeBlanc M, Crowley JJ, Grossman HB, Natale RB, Wozniak AJ, Berenson JR, List AF, Peters WA, Flanigan RC, Macdonald JS, Al-Sarraf M, Thompson IM, Coltman CA. Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lecture. J Clin Oncol. 2003 Dec 01; 21(23 Suppl):246s-252s. PMID: 14645404.
      Citations: 1     Fields:    Translation:Humans
    430. Syed S, Eng TY, Thomas CR, Thompson IM, Weiss GR. Current issues in the management of advanced squamous cell carcinoma of the penis. Urol Oncol. 2003 Nov-Dec; 21(6):431-8. PMID: 14693269.
      Citations: 4     Fields:    Translation:Humans
    431. Bermejo CE, Coursey J, Basler J, Austenfeld M, Thompson I. Histologic confirmation of lesions identified by Prostascint scan following definitive treatment. Urol Oncol. 2003 Sep-Oct; 21(5):349-52; discussion 353. PMID: 14670541.
      Citations: 7     Fields:    Translation:Humans
    432. Thompson I, Leach RJ, Pollock BH, Naylor SL. Prostate cancer and prostate-specific antigen: the more we know, the less we understand. J Natl Cancer Inst. 2003 Jul 16; 95(14):1027-8. PMID: 12865440.
      Citations: 2     Fields:    Translation:HumansCells
    433. Leslie JA, Stegemann L, Miller AR, Thompson IM. Metastatic seminoma presenting with pulmonary embolus, inferior vena caval thrombosis, and gastrointestinal bleeding. Urology. 2003 Jul; 62(1):144. PMID: 12837446.
      Citations: 4     Fields:    Translation:Humans
    434. Kamerer A, Basler J, Thompson I. Novel technique of Vest suture vesicourethral anastomosis in morbidly obese patient undergoing radical retropubic prostatectomy. J Urol. 2003 Jul; 170(1):174. PMID: 12796674.
      Citations: 1     Fields:    Translation:Humans
    435. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003 Jul 17; 349(3):215-24. PMID: 12824459.
      Citations: 644     Fields:    Translation:HumansCTClinical Trials
    436. Hammad AM, Paris GR, van Heuven WA, Thompson IM, Fitzsimmons TD. Spontaneous regression of choroidal metastasis from renal cell carcinoma. Am J Ophthalmol. 2003 Jun; 135(6):911-3. PMID: 12788144.
      Citations: 6     Fields:    Translation:Humans
    437. Tangen CM, Faulkner JR, Crawford ED, Thompson IM, Hirano D, Eisenberger M, Hussain M. Ten-year survival in patients with metastatic prostate cancer. Clin Prostate Cancer. 2003 Jun; 2(1):41-5. PMID: 15046683.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    438. Syed S, Petrylak DP, Thompson IM. Management of high-risk localized prostate cancer: the integration of local and systemic therapy approaches. Urol Oncol. 2003 May-Jun; 21(3):235-43. PMID: 12810212.
      Citations: 1     Fields:    Translation:HumansAnimals
    439. Leach R, Pollock B, Basler J, Troyer D, Naylor S, Thompson IM. Chemoprevention of prostate cancer. Focus on key opportunities and clinical trials. Urol Clin North Am. 2003 May; 30(2):227-37. PMID: 12735500.
      Citations: 3     Fields:    Translation:Humans
    440. Klein EA, Lippman SM, Thompson IM, Goodman PJ, Albanes D, Taylor PR, Coltman C. The selenium and vitamin E cancer prevention trial. World J Urol. 2003 May; 21(1):21-7. PMID: 12756490.
      Citations: 13     Fields:    Translation:Humans
    441. Thompson IM, Basler J, Hensley D, von Merveldt D, Jenkins CA, Higgins B, Leach R, Troyer D, Pollock B. Prostate cancer prevention: what do we know now and when will we know more? Clin Prostate Cancer. 2003 Mar; 1(4):215-20. PMID: 15040879.
      Citations: 1     Fields:    Translation:Humans
    442. Thompson IM, Tangen C, Goodman P. The Prostate Cancer Prevention Trial: design, status, and promise. World J Urol. 2003 May; 21(1):28-30. PMID: 12756491.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    443. Grizzle WE, Adam BL, Bigbee WL, Conrads TP, Carroll C, Feng Z, Izbicka E, Jendoubi M, Johnsey D, Kagan J, Leach RJ, McCarthy DB, Semmes OJ, Srivastava S, Srivastava S, Thompson IM, Thornquist MD, Verma M, Zhang Z, Zou Z. Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer. Dis Markers. 2003-2004; 19(4-5):185-95. PMID: 15258333.
      Citations: 13     Fields:    Translation:Humans
    444. Leslie JA, Prihoda T, Thompson IM. Serendipitous renal cell carcinoma in the post-CT era: continued evidence in improved outcomes. Urol Oncol. 2003 Jan-Feb; 21(1):39-44. PMID: 12684126.
      Citations: 8     Fields:    Translation:Humans
    445. Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, Taylor PR, Coltman C. SELECT: the selenium and vitamin E cancer prevention trial. Urol Oncol. 2003 Jan-Feb; 21(1):59-65. PMID: 12684129.
      Citations: 21     Fields:    Translation:Humans
    446. Thompson IM, Basler JA, Leach R, Troyer D, Klein E, Brawley O. Challenges and opportunities to the design and implementation of chemoprevention trials for prostate cancer. Urol Oncol. 2003 Jan-Feb; 21(1):73-8. PMID: 12684131.
      Citations:    Fields:    Translation:Humans
    447. Corbin NS, Thompson I. Urology and the Nobel Prize. Urol Oncol. 2003 Jan-Feb; 21(1):83-5. PMID: 12684132.
      Citations:    Fields:    Translation:Humans
    448. Thompson IM. Informed consent for prostate cancer screening--a call for equity in medical interventions. Urology. 2003 Jan; 61(1):15-6. PMID: 12559257.
      Citations:    Fields:    Translation:HumansPHPublic Health
    449. Glass TR, Tangen CM, Crawford ED, Thompson I. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol. 2003 Jan; 169(1):164-9. PMID: 12478127.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    450. Ibarra R, Magee C, Ferral H, Thompson IM. Post-prostatectomy bleeding managed by endovascular embolization. J Urol. 2003 Jan; 169(1):276-7. PMID: 12478158.
      Citations: 2     Fields:    Translation:Humans
    451. Sebesta M, Cespedes RD, Luhman E, Optenberg S, Thompson IM. Questionnaire-based outcomes of urinary incontinence and satisfaction rates after radical prostatectomy in a national study population. Urology. 2002 Dec; 60(6):1055-8. PMID: 12475669.
      Citations: 4     Fields:    Translation:Humans
    452. Pauler DK, Gower KB, Goodman PJ, Crowley JJ, Thompson IM. Biomarker-based methods for determining noncompliance in a prevention trial. Control Clin Trials. 2002 Dec; 23(6):675-85. PMID: 12505245.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    453. Thompson IM. Prostate cancer: wait or treat? How to apply new findings to your individual situation. Health News. 2002 Nov; 8(11):5. PMID: 12523249.
      Citations:    Fields:    Translation:Humans
    454. Powell IJ, Tangen CM, Miller GJ, Lowe BA, Haas G, Carroll PR, Osswald MB, DeVERE WHITE R, Thompson IM, Crawford ED. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109. J Urol. 2002 Nov; 168(5):2016-9. PMID: 12394698.
      Citations: 15     Fields:    Translation:Humans
    455. Balic I, Graham ST, Troyer DA, Higgins BA, Pollock BH, Johnson-Pais TL, Thompson IM, Leach RJ. Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men. J Urol. 2002 Nov; 168(5):2245-8. PMID: 12394768.
      Citations: 9     Fields:    Translation:HumansCells
    456. Nisbet AA, Thompson IM. Impact of diabetes mellitus on the presentation and outcomes of Fournier's gangrene. Urology. 2002 Nov; 60(5):775-9. PMID: 12429294.
      Citations: 22     Fields:    Translation:Humans
    457. Peña AA, Bermejo CE, Thompson IM. Ventral bladder hernia following tubal ligation. J Urol. 2002 Oct; 168(4 Pt 1):1502. PMID: 12352435.
      Citations:    Fields:    Translation:Humans
    458. Thompson IM, Tangen C, Basler J, Crawford ED. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol. 2002 Sep; 168(3):1008-12. PMID: 12187210.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    459. Pelaez C, Leslie JA, Thompson IM. Adenocarcinoma in a colon conduit. J Urol. 2002 Apr; 167(4):1780. PMID: 11912410.
      Citations: 1     Fields:    Translation:Humans
    460. Zimmerman RA, Thompson IM. Prevalence of complementary medicine in urologic practice. A review of recent studies with emphasis on use among prostate cancer patients. Urol Clin North Am. 2002 Feb; 29(1):1-9, vii. PMID: 12109336.
      Citations: 2     Fields:    Translation:Humans
    461. Plaetke R, Thompson I, Sarosdy M, Harris JM, Troyer D, Arar NH. Genetic fieldwork for hereditary prostate cancer studies. Urol Oncol. 2002 Jan-Feb; 7(1):19-27. PMID: 12474537.
      Citations: 3     Fields:    Translation:Humans
    462. Thompson IM. Pharmacologic agents in complementary medicine in prostatic disease. Drugs Today (Barc). 2001 Jun; 37(6):427-433. PMID: 12764428.
      Citations: 2     Fields:    
    463. Thompson I. Distinguishing benign from malignant prostate disease. Can J Urol. 1997 Jun; 4(2 Supp 1):18-21. PMID: 12735829.
      Citations:    Fields:    
    THOMPSON's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (895)
    Explore
    _
    Co-Authors (26)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _